Trading Analysis Report: LLY¶
- Analysis date: 2026-10-14
- Rating: Underweight
- Generated: 2026-10-14 17:32:22
- TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
- Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
- Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket
I. Analyst Team Reports¶
Market Analyst¶
Current Price: 1208.74 Price As Of: 2026-10-14
LLY (Eli Lilly and Company, NYQ): Technical Report as of 2026-10-14¶
The verified snapshot is the source of truth for every exact price and indicator value below. The indicator tool outputs for RSI, ATR and MACD histogram matched the snapshot, so I found no discrepancies. Percentages I derived myself come from the dated closes in the tool output.
1. Indicators chosen and why¶
I used eight indicators plus the moving averages and Bollinger Bands already in the snapshot. The goal was one or two per category, with no redundant pairs.
| Role | Indicator | Why it fits LLY now |
|---|---|---|
| Trend and regime | supertrend (weekly, monthly, daily) | Gives the primary trend, regime context and a concrete trailing stop. The tiers currently disagree. |
| Trend strength | adx | LLY has swung between a trendless chop and a brief directional burst, so I need to know whether trend signals are reliable. |
| Momentum | macdh | Shows whether the bounce is accelerating or fading. |
| Momentum | rsi | Checks overbought and oversold levels. I did not add stochrsi, which would be redundant. |
| Volatility | atr | Sizes stops and positions. Bollinger levels come from the snapshot. |
| Volume | obv | Tests whether volume confirms the price recovery. |
| Exhaustion | td_9 | Weekly, monthly and daily exhaustion counts. |
| Stretch | z_score | Quantifies how extended today's jump is on each timeframe. |
2. Today's bar (verified)¶
- OHLC: Open 1177.87, High 1216.71, Low 1174.24, Close 1208.74.
- Day change: The prior close on 2026-10-13 was 1166.51, so the close is +42.23 (+3.62%).
- Candle shape: The close sits in the upper ~81% of the day's range. The ~8-point upper wick means sellers capped the high near 1216.71.
- Volume: 3,162,617 shares, about 1.4x the ~2.2M average of the prior 20 sessions (my calculation from the price data).
- Volume caveat: This figure isn't rounded to the hundreds like the other bars, so it may be provisional. Re-check it once the session is final.
- New 30-day high: 1208.74 is the highest close in the 30-row verification window. The previous highs in that window were 1188.72 (10-07) and 1184.78 (09-28).
3. Big picture from the one-year price history¶
- Recovery from the April low: LLY fell from the ~1100s in early 2026 to a low close of 848.53 on 2026-04-29. It then jumped to 931.66 on 04-30 (+9.8% on 8.24M shares) and rallied to the 1200s by late June.
- Range since late June: Closes have stayed between 1114.08 (08-04) and 1280.34 (08-19), the highest close in the dataset. The intraday high of 1292.65 was also on 08-19.
- Double-bottom area: The closing lows of 1114.08 (08-04) and 1115.70 (09-11) are nearly equal. That is an observation, not a validated support level.
- Today's position: Price is about 5.6% below the 08-19 closing high (1208.74 vs 1280.34). It is in the upper-middle of the multi-month range.
- Gap risk: Several sessions gapped sharply on heavy volume:
- 2026-02-04: +10.3%, 7.12M shares
- 2026-04-30: +9.8%, 8.24M shares
- 2026-06-26: +7.1%, 7.73M shares
- 2026-08-05: +4.9%, 6.45M shares
These moves dwarf the 34.42 ATR. My tools give no earnings calendar or news, so check for scheduled events before sizing.
4. Trend¶
Moving averages (snapshot): - The 10 EMA is 1176.39, the 50 SMA is 1177.17 and the 200 SMA is 1075.89. - Price is above all three: about 2.8% above the 10 EMA, 2.7% above the 50 SMA and 12.3% above the 200 SMA. - The 10 EMA and 50 SMA are almost identical (0.78 apart). That 1176–1177 cluster is the nearest meaningful dynamic support. - The 50 SMA is above the 200 SMA, which is a bullish long-term structure. I haven't pulled the date of that crossover.
SuperTrend, with higher tiers weighted more: - Weekly (primary): UP. The stop is 979.49, and the close is 23.40% above it. - Monthly (regime): UP. The stop is 781.21, and the close is 54.73% above it. - Daily (entry timing): DOWN. The stop line is at 1217.65, and the close is 0.73% below it. - Reading: The primary and regime trends are up. The only dissent is the daily tier, and it sits 8.91 points above today's close. Today's high of 1216.71 fell 0.94 short of that line. A daily close above 1217.65 would flip the daily tier to up and bring all three tiers into agreement.
ADX (trend strength): - ADX is 20.11. It peaked at 31.01 on 10-07 and fell to 19.34 on 10-13. - It was 4.98 on 09-18, which was a very flat market. - A reading near 20 sits at the "range-bound" boundary and does not confirm a tradable trend. I did not pull +DI and -DI, so I can't give directional pressure from them. - Trend-following breakout signals deserve extra confirmation while ADX is this low.
5. Momentum¶
MACD (snapshot): - The MACD line is 4.87, the signal is 0.53 and the histogram is 4.34. - The histogram turned positive on 10-07, moving from -0.11 to +2.11. It has stayed positive since then and is now at its highest level since 09-30 (4.31). - Both MACD lines are only slightly above zero, so this is a recovery from neutral rather than a strong trend. - The prior histogram peak was 6.32 on 09-29, when the close was 1184.63. Price is now higher at 1208.74, but the histogram is lower. This is not a divergence yet. If price makes new highs while the histogram stays under ~6.3, treat that as a warning.
RSI: - RSI is 60.44, the highest reading in the 30-day window. It was 49.99 on 10-13 and 42.06 on 09-15. - It is constructive and has room before the 70 threshold, so momentum is not overbought.
6. Volatility and risk sizing¶
Bollinger Bands (snapshot): - The middle band is 1168.60, the upper is 1204.14 and the lower is 1133.06. - The close is 4.60 above the upper band, a short-term extension. - Bandwidth is about 6.1% of the middle band. - Closes above the upper band can lead to continuation or to a pullback toward the middle. Context from the z-score and ADX points toward the pullback case.
ATR: - ATR is 34.42, about 2.85% of price, and has been steady at 29.5–34.9 over the past month. - 1 ATR is about 34.4 points. 1.5 ATR below the close is about 1157. 2 ATR below is about 1140, close to the early-October closes of 1142.85 and 1143.12. - The weekly SuperTrend stop is 23% away, which is too wide for tactical sizing. It is useful only as a structural line.
7. Volume¶
- OBV is 347.87M. It rose from 334.76M on 09-14, so accumulation has outweighed distribution over the month.
- OBV is still about 2.0M below its 09-28 peak of 349.87M, while price made a higher close today. The volume confirmation is incomplete.
- A convincing breakout would need OBV above ~349.9M and sustained above-average volume. Today's volume is a good start but unconfirmed.
8. Exhaustion and stretch¶
TD-9 (negative counts are sell-setups, per the tool): - Weekly: -2 of 9. - Monthly: -6 of 9. - Daily: -1 of 9. - No tier is near a completed 9 on the weekly or daily charts. The monthly -6 is worth tracking because it could approach 9 over the next few months.
Z-score (20-period): - Weekly: +1.02. - Monthly: +1.41. - Daily: +2.26. - Only the daily tier is stretched, and the higher tiers are not. The daily stretch agrees with the close above the upper Bollinger Band. It suggests short-term mean-reversion risk toward the 1168–1177 zone, not a trend reversal.
9. Synthesis¶
Bias: The structure is constructive. All three moving averages are below price, the weekly and monthly SuperTrend are up, MACD has turned positive, RSI is rising and OBV is up over the month. Against that, the move is short-term extended, ADX doesn't confirm a trend, the daily SuperTrend is still down, and OBV hasn't yet confirmed today's high.
Bullish continuation: - Trigger: a daily close above 1217.65. - Quality checks: volume above ~2.2M, OBV above 349.87M, and ADX back above 25. - Overhead levels from the data: 1230.18 (08-10 close), 1236.23 (highs on 06-29 and 08-11), 1244–1255 (08-20 and 08-21 closes), 1280.34 (08-19 close) and 1292.65 (08-19 high).
Pullback or mean reversion: - First support: 1204.14 (upper band), then 1176–1177 (10 EMA and 50 SMA), then 1168.60 (middle band) and 1166.51 (the 10-13 close). - Deeper levels: 1142.85–1143.12 (early-October closes) and 1133.06 (lower band). - A close below roughly 1115 would break the 08-04 and 09-11 closing lows (1114.08, 1115.70) and weaken the range-bound constructive picture. The 200 SMA is at 1075.89.
What I would watch: whether price holds above 1204–1177 after today's pop, whether the daily SuperTrend flips, and whether volume and OBV confirm.
10. Limitations¶
- I had no news, earnings-calendar or fundamental data, so event risk is unassessed.
- Indicator histories covered only 30 days.
- +DI and -DI were not pulled.
- I haven't tested whether any of these levels held as support or resistance in the past, so they are reference levels, not validated ones.
- The 10-14 volume may be provisional.
Summary table¶
| Item | Value / Reading | Interpretation |
|---|---|---|
| Close (2026-10-14) | 1208.74 (+3.62% on the day) | New 30-day closing high, ~5.6% below the 08-19 high close of 1280.34 |
| Day range | 1174.24–1216.71 | Closed in the upper ~81% of the range; upper wick near the daily SuperTrend line |
| 10 EMA / 50 SMA / 200 SMA | 1176.39 / 1177.17 / 1075.89 | Price above all; 1176–1177 is the nearest support cluster |
| SuperTrend weekly / monthly | UP, stop 979.49 / UP, stop 781.21 | Primary and regime trends up |
| SuperTrend daily | DOWN, stop 1217.65 (close 0.73% below) | A close above 1217.65 flips it up |
| ADX | 20.11 (31.01 on 10-07, 4.98 on 09-18) | No confirmed trend; breakouts need extra confirmation |
| MACD / signal / histogram | 4.87 / 0.53 / 4.34 | Positive since 10-07 but below the 6.32 peak on 09-29 |
| RSI | 60.44 | Constructive, not overbought |
| Bollinger (lower / mid / upper) | 1133.06 / 1168.60 / 1204.14 | Close is 4.60 above the upper band, a short-term extension |
| ATR | 34.42 (~2.85% of price) | 2 ATR below the close is about 1140 |
| OBV | 347.87M (peak 349.87M on 09-28) | Up over the month, but not yet confirming today's high |
| TD-9 weekly / monthly / daily | -2 / -6 / -1 | No imminent exhaustion; monthly -6 is a slow-burn watch |
| Z-score weekly / monthly / daily | +1.02 / +1.41 / +2.26 | Only the daily tier is stretched; pullback risk, not trend failure |
| Upside levels | 1217.65, 1230.18, 1236.23, 1244–1255, 1280.34, 1292.65 | Daily SuperTrend line first, then prior highs |
| Downside levels | 1204.14, 1176–1177, 1168.60, 1142.85, 1133.06, 1115, 1075.89 | Support ladder; a break below ~1115 weakens the range |
| Data gaps | No news, earnings calendar or +DI/-DI; volume may be provisional | Check event risk before sizing |
Sentiment Analyst¶
Overall Sentiment: Mildly Bullish (Score: 6.3/10) Confidence: Low
LLY sentiment for 2026-10-07 to 2026-10-14 leans clearly positive, driven mostly by a defensive rotation into big pharma on 2026-10-14. The data is thin: Reddit is unavailable, the news is headline-only, and the StockTwits sample covers about five hours of one day. Confidence is therefore low.
1. Source-by-source breakdown
News (Yahoo Finance, 19 items, about 18 unique; the Nasdaq/Russell 2000 piece appears twice via CNW and PR Newswire). Only headlines were provided, with no body text and no per-item dates, so I cannot order events inside the window. Reading the headlines: - Positive for LLY: Barron's 'Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.'; Simply Wall St 'Stock Looks Undervalued As Its 404% Run Continues'; Simply Wall St on early Taltz and Zepbound biomarker synergies changing the investment story; Trefis 'What Is Eli Lilly Stock's Biggest Opportunity?'; GuruFocus on Walmart expanding free prescription coverage to Ozempic and Mounjaro for employees. The Walmart item is a modest access signal for the GLP-1 class and also benefits Novo's Ozempic. - Cautionary: Zacks 'Here's Why Eli Lilly (LLY) Fell More Than Broader Market', which shows at least one down day for LLY in the window, date unknown. Competitive obesity pipeline headlines: Roche adding an RNAi obesity candidate (Zacks) and Viking's oral obesity candidate entering Phase 3 (Stocktwits). The peer-reaction headline 'J&J Beat and Raised. The Stock Fell Anyway.' (24/7 Wall St.) is a reminder that good prints do not guarantee good reactions. - Macro backdrop: IBD reports an AI-led tech sell-off (Dell, AMD, CoreWeave) and Nasdaq down 1.65% with Russell 2000 at RSI 28. This is the context for the defensive bid in healthcare. - Neutral or event-driven: Barchart 'Eli Lilly Earnings Preview: What to Expect', Motley Fool BMY vs. LLY, and generic ETF, dividend, oncology-spending and Sangamo items. Net news read: mildly positive, with strength attributed to sector rotation and valuation framing, and with competition and earnings-reaction caveats.
StockTwits (30 most recent messages, all dated 2026-10-14, 18:11Z to 23:12Z). Tagged sentiment is 8 Bullish (27%), 1 Bearish (3%) and 21 unlabeled. Among labeled posts that is 8 of 9 bullish (about 89%), but n=9 is too small to treat as a robust ratio. Quality adjustments: - Several tagged posts are really about other tickers. The one Bearish tag (@Optionking1995) is a joke about VKTX's takeover valuation and not a bearish view on LLY. The Bullish tag from @Achandler787 is about CABA and urges LLY to partner or buy. @THECORLEONEFAMILY is only a ticker list and @JFDI is an empty $LLY post. So genuinely LLY-specific bullish opinion is closer to 4-5 posts: @LLYBULL ('new All Time Highs'), @DickStockman (hoping for a close above $1205), @janthony23 (healthcare as an offset to a tech sell-off) and @InItToWinIt100 ('Market cap now $1.14 Trillion'). @chrsc is also bullish but is mainly about a prior pick. - @topstockalerts posted four near-identical, content-free 'strength' lines, and @algotradealert looks automated. Both deserve low weight. - Unlabeled content echoes the rotation theme: @notreload_ai says LLY, MRK, ABBV and UNH rose as markets fell on stronger inflation data, @Gebinator notes JNJ, MRK, ABBV and LLY had a great day amid a brutal market, and @TwoToesTrading describes LLY calls grinding at the high of day. Price targets are casual and unsupported, for example @marione's 'tomorrow 1,290'. - Cautionary voice: @oconnor007 says LLY 'is gonna have to correct sooner or later'. @kcphaeton's FTC/Shkreli post lists LLY among many tickers with no evidence of any LLY exposure, so I treat it as noise. - Price levels (about $1,200, ATH, $1.14T market cap) come from user posts only. No price data was provided, so these are unverified. - The window is a single afternoon and evening, so it shows intraday mood on a strong day, not a week-long trend.
Reddit (r/wallstreetbets, r/stocks, r/investing). Skipped by configuration, so there is no data and no signal. A longer-horizon and more contrarian read is missing.
2. Cross-source alignment and divergence - Alignment: news (Barron's 'healthcare is rallying') and StockTwits agree that LLY outperformed while tech and the broader market sold off. Both attribute it largely to defensive rotation around hot inflation data and the AI/tech sell-off. - Divergence in tone: retail is more euphoric (all-time highs, market-cap milestones, price-target chatter, M&A speculation), while the news mix is more balanced. It adds a down-day headline, competitive obesity pipeline news, and peer earnings-reaction caution. Retail enthusiasm looks reactive to price action, not driven by new LLY fundamentals. - No source shows meaningful LLY-specific bearish conviction. The main caution comes from implied valuation, positioning and event risk, not from negative commentary.
3. Dominant narrative themes 1. Defensive rotation: money moving from AI/tech and small caps into big pharma (LLY, MRK, ABBV, JNJ, UNH) on hotter CPI and a falling Nasdaq. 2. Momentum and valuation: all-time highs, a claimed $1.14T market cap, the '404% run', and a Simply Wall St 'undervalued' framing against 'must correct' remarks. 3. GLP-1 leadership: retail frames LLY as 'destroying' Novo, with next-generation GLP-1 work and broader access (Walmart coverage). Counterweights are new entrants and pipelines from Roche and Viking. 4. Dealmaking speculation: retail posts float LLY as acquirer or partner for CABA, MRNA, VKTX and SLS. This is speculative, uncorroborated by any news item, and mostly cross-promotion by holders of those other tickers. 5. Earnings anticipation: the Barchart preview and a StockTwits post citing a Q3 2026 report on October 29. The date appears only in a social post and is not confirmed in the headlines.
4. Catalysts and risks - Catalysts: the Q3 2026 earnings report (reportedly October 29); continued rotation into defensives if the tech sell-off and inflation concerns persist; oncology pipeline news and analyst enthusiasm (cited in an unverified social post); Zepbound/Taltz biomarker synergy narrative; expanding GLP-1 coverage such as Walmart's. - Risks: a reversal of the rotation if tech stabilizes, since the move may be macro-driven and not LLY-specific; crowded retail enthusiasm at all-time highs, where an 89% bullish labeled ratio and 'to the moon' tone can precede pullbacks (small sample, though); the J&J precedent of a beat-and-raise followed by a sell-off, which suggests high earnings expectations; competitive obesity pipelines (Roche RNAi, Viking oral Phase 3, Novo); valuation after a very large multi-year run; and reliance on unverified user-quoted price levels. - Data gaps: no Reddit data, headline-only news without dates, a one-day StockTwits window with a heavy unlabeled and promotional share, and no price or volume data supplied.
5. Summary table
| Signal | Direction | Source | Supporting evidence |
|---|---|---|---|
| Healthcare/pharma defensive rotation | Bullish | News + StockTwits | Barron's 'Lilly, Merck, AbbVie Surge'; @notreload_ai and @Gebinator: LLY/MRK/ABBV/JNJ up as market fell; Nasdaq -1.65% |
| Retail labeled ratio | Bullish (low reliability) | StockTwits | 8 Bullish / 1 Bearish / 21 unlabeled of 30; the Bearish tag is about VKTX; several Bullish tags are about other tickers |
| All-time-high / market-cap enthusiasm | Bullish, contrarian risk | StockTwits | @LLYBULL 'new All Time Highs'; @InItToWinIt100 '$1.14 Trillion'; @DickStockman $1205 level (unverified) |
| Valuation framing | Mildly Bullish | News | Simply Wall St 'Undervalued As Its 404% Run Continues' |
| Correction caution | Mildly Bearish | StockTwits | @oconnor007 'gonna have to correct sooner or later' |
| Down day vs market | Mildly Bearish | News | Zacks 'Fell More Than Broader Market' (date unknown) |
| Obesity competition | Mildly Bearish | News | Roche RNAi candidate; Viking oral obesity Phase 3 |
| GLP-1 access / franchise strength | Mildly Bullish | News + StockTwits | Walmart Ozempic/Mounjaro coverage; Taltz/Zepbound synergy piece; retail 'destroying Novo' remarks |
| M&A / partnership chatter | Speculative | StockTwits | CABA, MRNA, VKTX, SLS posts; no news corroboration |
| Earnings event risk | Neutral (two-sided) | News + StockTwits | Barchart earnings preview; Q3 report reportedly October 29; J&J beat-and-fall precedent |
| Reddit sentiment | No data | Disabled by config |
News Analyst¶
LLY (Eli Lilly and Company): news and macro report for the week to 2026-10-14¶
Data coverage¶
- FRED macro data failed. All seven calls (fed funds, 10-year Treasury, CPI, unemployment, yield curve, VIX) returned
DATA_UNAVAILABLEbecause the FRED API key isn't set. I have no verified figures for rates, inflation, labor or volatility, and I haven't estimated any. Macro color below comes only from headlines and prediction markets. - The news tools returned headlines and links only, with no article text or publication dates. I can't verify specific numbers, dates or which day a move happened. Treat the headline-derived points as leads to confirm.
- Polymarket has no markets on orforglipron approval or on pharma tariffs and drug pricing. Those gaps are not evidence of low risk.
1. Macro backdrop¶
Rates and the Fed (prediction-market data)¶
The market is pricing a hawkish tilt for the Oct 28–29 FOMC meeting (market resolves 10/29):
| Outcome | Probability | 1-week change | Volume |
|---|---|---|---|
| No change | 70% | −13pp | ~$11.7M |
| +25bp hike | 28% | +13pp | ~$9.3M |
| −25bp cut | ~0% | −0.1pp | ~$6.9M |
| +50bp or more hike | 1% | +0.2pp | ~$5.3M |
- "No Fed rate cuts in 2026" is priced at 97% (+1.2pp on the week, ~$8.9M volume). Cut-count markets for 6, 9, 10 and 11 or more cuts are all at ~0%.
- In one week the odds of a hike rose from roughly 15% to 28%. That fits the "10-year Treasury yield rises following hot inflation data" headline, though I can't confirm the specific CPI print.
- US recession by end of 2026 is priced at 8% (+1pp on the week, ~$2.3M volume). The market sees a rates and inflation problem, not a growth scare.
Yields and credit (headlines only)¶
- Headlines say the 10-year yield rose after hot inflation data and that bond yields are "surging worldwide," with France on the "ugly side."
- A headline says mortgage rates are at their highest in nearly three years, with a separate "Is 8% next?" piece.
- BofA's fund manager survey headline says managers won't rotate from stocks to bonds until yields hit 5.9%.
- BlackRock is described as "suddenly more bearish on stocks." Other headlines flag "bubble-like valuations and debt crisis chatter."
Equities and rotation¶
- Tech and AI took a hit: a headline says Nasdaq fell 1.65% and the Russell 2000 hit an RSI of 28 (oversold). IBD's headline cites an AI-led sell-off hitting Dell, AMD and CoreWeave, with "Anthropic news" as the catalyst.
- Another headline says tech rebounded as AI-trade jitters eased, so the tape looks choppy.
- Banks rose on JPMorgan and Goldman earnings while chips fell.
- Barron's has a headline that "Lilly, Merck, AbbVie stocks surge" on a healthcare rally. I can't date it from the tool output.
Geopolitics and commodities¶
- Oil is around $103, per the headline "Oil falls to $103 as Trump says US will not attack Iran before the midterm elections." Oil is elevated and headline-sensitive.
- Gold and silver slid on one headline day.
- Polymarket has small, thin markets on IEA stock releases by France and Germany. Volumes are under $5K, so I wouldn't read much into them.
- Sustained oil near $100 feeds inflation, which supports the hawkish Fed pricing above.
2. LLY-specific news¶
Sentiment and positioning¶
- Simply Wall St. says LLY "looks undervalued as its 404% run continues." That is a valuation-model headline. It shows LLY is a momentum and quality-growth name, not that the stock is cheap.
- Comparison pieces (Motley Fool's BMS vs. LLY, Trefis on LLY's "biggest opportunity") are retail-oriented and carry little new information.
- Zacks has a headline "Here's why Eli Lilly (LLY) fell more than broader market." I can't date it, but it shows LLY isn't immune on risk-off days.
Earnings¶
- Barchart has an "Eli Lilly earnings preview: what to expect." The tool didn't give the report date or consensus numbers. Confirm the Q3 date, which is typically late Oct or early Nov, before sizing positions around it.
- The J&J headline "Beat and raised, stock fell anyway" is a read-through. Large-cap pharma earnings are not getting rewarded automatically in this tape, so the bar for LLY is likely high.
Competition in obesity¶
- Viking's oral obesity pill has entered Phase 3. This adds long-dated competitive pressure to LLY's obesity franchise.
- Roche is expanding its obesity pipeline with an RNAi candidate from Rona. It is early-stage and a longer-term competitive theme.
- Both are slow-burn narrative risks, not near-term earnings risks.
Demand and access¶
- Walmart is expanding free prescription coverage to Ozempic and Mounjaro for employees. Mounjaro is LLY's tirzepatide. This suggests growing employer coverage of GLP-1s, which helps volume. Employer coverage details and any pricing concessions aren't in the headline.
- A Simply Wall St. piece covers early Taltz and Zepbound biomarker synergies and how they've changed the investment story. It points to diversification beyond a pure GLP-1 thesis, but no details were retrieved.
Regulatory and catalysts¶
- Polymarket prices "FDA approves Retatrutide this year" at 3% (−1.6pp on the week, ~$595K volume). A 2026 approval is essentially not expected, so don't build near-term trades on it. This says nothing about the drug's clinical outlook.
- I found no coverage of drug pricing, tariff or MFN (most-favored-nation) policy this week. That is a gap, not a clean bill of health.
3. Implications for LLY¶
- Hawkish-rate risk is the main macro headwind. The odds of a hike on Oct 29 rose 13pp in a week. LLY trades at a premium growth multiple, so it is sensitive to higher real yields. A hike or hawkish guidance would likely pressure long-duration growth stocks, LLY included.
- LLY may act as a defensive growth name in an AI sell-off. The healthcare rally headline and tech weakness point to rotation into pharma. That is a hypothesis to test against price data, and it isn't established by these headlines.
- Earnings are the nearest company catalyst. Confirm the date and consensus. After J&J fell on a beat and raise, expectations and guidance matter more than the headline beat.
- Competition is a narrative overhang, not a near-term P&L threat. Viking Phase 3 and Roche's RNAi are years from commercial impact.
- Oil near $103 and geopolitics are tail risks to inflation and Fed pricing. The Iran headline suggests a pause in escalation before the midterms, but that is a political statement and not a durable resolution.
4. Gaps for the next analyst¶
- Get LLY price, volume and technicals, including whether it is near highs, its RSI and relative strength vs. XLV and the S&P 500.
- Confirm the Q3 earnings date and consensus EPS and revenue (Mounjaro, Zepbound, Verzenio, Taltz).
- Read the underlying CPI print, the real 10-year yield and the VIX level, since FRED was unavailable.
- Check the status of drug-pricing, MFN and tariff policy, and any orforglipron regulatory timeline.
Summary table¶
| Category | Key point | Source type | Confidence | LLY implication |
|---|---|---|---|---|
| Fed Oct 28–29 | 70% hold, 28% hike (+13pp/wk), ~0% cut | Polymarket (deep volume) | High | Bearish for long-duration growth multiples |
| 2026 cuts | 97% "no cuts in 2026" | Polymarket | High | Higher-for-longer rates persist |
| Recession | 8% by end of 2026 (+1pp/wk) | Polymarket | Medium-high | Growth scare is not the driver |
| Yields | 10-year rose after hot inflation; global yields surging; mortgage rates at ~3-year high | Headlines (unverified) | Medium | Valuation headwind |
| Oil / geopolitics | Oil ~$103; Trump says no Iran strike before midterms | Headline | Medium | Inflation risk; headline-driven volatility |
| Equities | Nasdaq −1.65% headline; Russell 2000 RSI 28; AI-led tech sell-off | Headlines | Medium | Possible rotation into healthcare |
| Healthcare tape | "Lilly, Merck, AbbVie surge" (undated) | Barron's headline | Low-medium | Supportive but needs date check |
| LLY valuation | "404% run," "undervalued" per Simply Wall St. | Headline | Low | Momentum name; model-based claim |
| Earnings | Preview published; date and consensus not retrieved; J&J fell despite beat and raise | Barchart / 24/7 headlines | Medium | Nearest catalyst; high expectations |
| Competition | Viking oral obesity pill in Phase 3; Roche RNAi candidate | Headlines | Medium | Long-dated narrative risk |
| Demand | Walmart covers Ozempic and Mounjaro for employees | GuruFocus headline | Medium | Modest positive for volume |
| Retatrutide | 3% odds of FDA approval in 2026 | Polymarket | Medium | Not a 2026 catalyst |
| Macro data (FRED) | CPI, unemployment, fed funds, yield curve and VIX all unavailable | Tool failure | n/a | No verified figures; don't rely on estimates |
Fundamentals Analyst¶
LLY (Eli Lilly and Company) – Fundamental Report (as of 2026-10-14)¶
1. Bottom line¶
- Growth: Revenue was $22.97B in Q2 2026, up 47.7% year over year. Net income was $7.10B and diluted EPS $7.94, up about 25% and 26% year over year.
- Margins: Revenue is growing faster than profit. Q2 net margin fell to 30.9%, from 36.4% a year earlier and 37.4% in Q1 2026.
- Balance sheet: Q2 2026 was a big step-up quarter. Total assets rose $25.7B, to $142.3B. Derived liabilities rose about $23B. Investing outflow was about $15.4B and financing inflow about $8.4B.
- Valuation: The stock trades at 40.6x trailing and 25.5x forward earnings, 31.8x book, and about 1% FCF yield. A lot of growth is already priced in.
- Insiders: There were no insider transactions in the past 7 days. Officers sold about $18.8M of stock in June–August 2026 at $1,150–$1,190. The last open-market insider buys were in August 2025, at $634–$692. Lilly Endowment (more than 10% holder) has not sold since May 2026.
2. Data notes¶
- The tools gave no spot price. I back-solved about $1,209 from P/E × EPS (40.575 × 29.79). Market cap is $1.077T, which implies about 891M shares.
- The income statement and cash flow tables have no Q4 columns, because Q4 only appears in 10-Ks. Q4 2025 figures below are derived from vendor TTM numbers minus three reported quarters. I assume TTM covers Q3'25–Q2'26.
- Q4 2025 revenue ≈ $19.29B.
- Q4 2025 net income ≈ $6.64B.
- Q4 2025 EPS ≈ $7.38.
- Operating income, gross profit and total liabilities are "unavailable (not tagged)" in the statements. I derived liabilities as assets minus equity.
- Cash flow figures are year-to-date, so I derived Q2 by subtraction. The capex row is blank for recent periods, so FCF can't be rebuilt from the statements. I rely on the vendor's TTM FCF.
3. Profile and valuation (vendor snapshot)¶
| Metric | Value | Comment |
|---|---|---|
| Market cap | $1.077T | |
| P/E (TTM) / Forward | 40.6x / 25.5x | Annualized H1'26 EPS ($32.40) gives about 37x |
| PEG | 1.13 | |
| Price/Book | 31.8x | Book value is $38.00 per share |
| EPS TTM / Forward | $29.79 / $47.48 | Forward is 59% higher. It is likely a next-fiscal-year, possibly non-GAAP estimate, so it is not like-for-like with trailing GAAP |
| Dividend yield | 0.59% | About $7.1 per share per year, roughly 24% of TTM EPS |
| Beta | 0.45 | Low |
| 52-week range | $783.85–$1,292.65 | Price is about 6.5% below the high |
| 50-day / 200-day average | $1,175.55 / $1,077.50 | Price is about 3% above the 50-day and 12% above the 200-day |
| Revenue / Gross profit / EBITDA / Net income (TTM) | $79.67B / $66.44B / $41.71B / $26.71B | Gross margin 83.4%, EBITDA margin 52.3% |
| Profit margin / Operating margin | 33.5% / 54.2% | See the discrepancy flagged below |
| ROE / ROA | 102% / 20.4% | ROE is inflated by a small equity base |
| Debt/Equity / Current ratio | 162% / 1.355 | Implied debt is about $55B, so net debt is about $46B |
| FCF (TTM) | $11.07B | About 41% of net income |
Derived multiples: P/S is about 13.5x, EV/EBITDA about 27x, and P/FCF about 97x.
4. Income statement trends (USD millions)¶
| Quarter | Revenue | YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Q1'25 | 12,729 | +45.2% | 82.5% | 2,759 | 21.7% | 3.06 |
| Q2'25 | 15,558 | +37.6% | 84.3% | 5,661 | 36.4% | 6.29 |
| Q3'25 | 17,601 | +53.9% | 82.9% | 5,582 | 31.7% | 6.21 |
| Q4'25 (derived) | ~19,292 | n/a | n/a | ~6,638 | ~34.4% | ~7.38 |
| Q1'26 | 19,799 | +55.5% | 81.9% | 7,396 | 37.4% | 8.26 |
| Q2'26 | 22,974 | +47.7% | 85.8% | 7,095 | 30.9% | 7.94 |
- H1 2026 versus H1 2025: Revenue was $42.8B versus $28.3B (+51%). Net income was $14.5B versus $8.4B (+72%). EPS was $16.20 versus $9.35.
- Sequential revenue: Q2 was up 16.0% from Q1. Q1 was up only about 2.6% from the derived Q4. Revenue re-accelerated in Q2.
- Q2 profit did not follow revenue:
- Gross profit rose about $3.5B from Q1, yet net income fell about $0.3B (−4%).
- Costs below gross profit (R&D, SG&A, other, tax) therefore rose sharply.
- The tool doesn't break these out. Acquired in-process R&D charges are one possible driver. Similar charges depressed Q3 2023 (net income −$57M) and Q3 2024 ($970M). This is a hypothesis to check in the 10-Q, not something the data confirms.
- Margin discrepancy: The vendor's 54.2% operating margin can't be reconciled with a 30.9% Q2 net margin without line items. Treat it as non-GAAP or adjusted until verified.
- Scale: Quarterly revenue is about 2.9 times its Q1 2022 level ($7.8B).
5. Balance sheet (USD millions)¶
| Item | Q3'25 | Q4'25 | Q1'26 | Q2'26 |
|---|---|---|---|---|
| Total assets | 114,935 | 112,476 | 116,576 | 142,283 |
| Current assets | 62,071 | 55,629 | 54,835 | 64,672 |
| Cash | 9,792 | 7,268 | 5,282 | 8,950 |
| Current liabilities | 40,141 | 35,228 | 36,634 | 47,741 |
| Equity | 23,793 | 26,535 | 31,198 | 33,879 |
| Derived total liabilities | 91,142 | 85,941 | 85,378 | 108,404 |
- Q2 saw a jump in non-current assets (about +$15.9B) and current liabilities (+$11.1B).
- Equity rose only about $2.7B in Q2, against $7.1B of net income. After roughly $1.6B of quarterly dividends (my estimate from the yield), the gap suggests buybacks or other equity reductions. This is an inference.
- Equity/assets fell to 23.8%, from 26.8% in Q1.
- The current ratio of 1.355 is adequate. Liquidity is fine, but leverage rose materially.
- Equity has grown from about $14.3B at Dec 2024 to $33.9B.
6. Cash flow (USD millions, year-to-date, Q2 derived)¶
| Period | Operating | Investing | Financing |
|---|---|---|---|
| 9M 2025 | 13,588 | −8,170 | 666 |
| Q1'26 | 5,333 | −3,916 | −3,470 |
| H1'26 | 16,023 | −19,312 | +4,956 |
| Q2'26 (derived) | ~10,690 | ~−15,396 | ~+8,426 |
- Operating cash flow is strong. H1'26 was $16.0B versus $4.75B in H1'25.
- Q2'26 operating cash flow was about 1.5x net income.
- Q2 investing outflow of about $15.4B was financed partly by new financing (about $8.4B). The tool doesn't split capex from acquisitions or investment purchases.
- TTM FCF of $11.07B is only about 41% of net income. That implies heavy capex or other reinvestment.
7. Insider activity (about 14 months of data)¶
Past 7 days: None. The latest entries are director stock awards on 2026-09-21 and small gifts on 9/2 and 9/9.
Open-market officer sales: | Date | Insider | Shares | Price | Value | |---|---|---|---|---| | 2026-08-17 | Jonsson (Officer) | 6,500 | $1,175.10 | $7.64M | | 2026-08-10 | Zakrowski (Officer) | 2,000 | $1,185.01 | $2.37M | | 2026-08-07 | Hakim (General Counsel, indirect) | 5,000 | $1,190.00 | $5.95M | | 2026-06-10 | Yuffa (Officer) | 2,500 | $1,150.77 | $2.88M |
- The four sales total about $18.8M.
- The tool doesn't show post-sale holdings, so I can't size them against each person's stake.
Open-market buys: The last ones were 12–15 August 2025, by seven insiders including CEO Ricks, the CFO and four directors/officers. They totaled about $4.4M at $634–$692. Those buys are up roughly 75–90% at the current price. There have been none since.
Lilly Endowment (more than 10% holder): - It sold about 3.86M shares for about $3.63B between Sep 2025 and May 2026. - Sep 2025–Jan 2026: about 3.84M shares. - 6 May 2026: 15,828 shares at about $996 ($15.8M). - Most of the volume was in Oct–Nov 2025 and 7 Jan 2026 (292,148 shares, $322M). - The round totals (3,540,000 and 300,000 shares in two blocks) suggest programmatic selling. That is my inference. - No sales since May 2026.
Awards: Monthly director awards of $5K–$16K per person are compensation, not a signal. Annual officer equity awards were granted 9 Feb 2026 (CEO Ricks: 38,913 shares, $40.7M).
8. What matters for traders¶
Supportive: - Revenue is growing about 48–55% year over year. Gross margin is about 82–86%, and operating cash flow is accelerating. - The stock sits above its 50-day and 200-day averages, and beta is low. - The Endowment overhang has been quiet since May.
Cautions: - Profit lagged revenue in Q2. Net income fell sequentially and the net margin compressed. - Leverage and liabilities jumped in one quarter. Interest expense and financing needs are worth watching. - Valuation is rich on trailing and cash-flow measures. The forward P/E of about 25x relies on EPS growth of about 59%. - Officers have sold near $1,175–$1,190 and there have been no insider buys for 14 months.
Items to verify: 1. What drove Q2 below-gross-profit costs and the roughly $23B rise in liabilities (debt, acquisitions, IPR&D, rebate accruals). Check the Q2 10-Q. 2. The Q3 2026 earnings date and results. The tools don't give a date. Lilly has historically reported around late October or early November, but that is unconfirmed here. 3. Whether the forward EPS of $47.48 is GAAP or non-GAAP, and for which fiscal year.
9. Summary table¶
| Category | Key point | Evidence | Read-through |
|---|---|---|---|
| Valuation | 40.6x trailing, 25.5x forward, P/B 31.8x, FCF yield about 1% | Vendor snapshot | Rich. Needs sustained growth |
| Price context | About $1,209 (derived) | P/E × EPS | 6.5% below the 52-week high, above the 50- and 200-day averages |
| Revenue | Q2'26 $22.97B, +47.7% YoY, +16% QoQ | Income statement | Strong, re-accelerating |
| Profitability | Q2 net margin 30.9% (vs 36.4% YoY, 37.4% Q1) | Income statement | Profit lagging revenue; cause unknown |
| Gross margin | Q2 85.8%, TTM 83.4% | Income statement, vendor | Very high |
| EPS | Q2 $7.94; H1 $16.20 (+73% YoY) | Income statement | Strong growth |
| Balance sheet | Assets $142.3B (+$25.7B QoQ); derived liabilities $108.4B | Balance sheet | Large step-up in leverage |
| Liquidity | Current ratio 1.355; cash $8.95B | Balance sheet | Adequate |
| Cash flow | H1'26 operating cash flow $16.0B; investing −$19.3B; financing +$5.0B | Cash flow | Strong operating cash flow, heavy reinvestment |
| FCF | $11.07B TTM, about 41% of net income | Vendor | Low conversion |
| Insider selling | About $18.8M of officer sales, Jun–Aug 2026 | Insider data | Modest; no holdings context |
| Insider buying | Last buys Aug 2025 at $634–$692 | Insider data | Stale, though well in the money |
| Lilly Endowment | About 3.86M shares (about $3.63B) sold Sep 2025–May 2026; none since | Insider data | Overhang paused |
| Past-week changes | No new filings or insider trades found | All tools | No new fundamental information this week |
| Data gaps | Missing Q4 columns, operating income, liabilities and capex; 54.2% operating margin unreconciled | Tool outputs | Verify with the 10-Q before relying on these |
II. Research Team Decision¶
Bull Researcher¶
Bull Analyst: # Bull Case for LLY (Eli Lilly and Company), as of 2026-10-14
The bear hasn't spoken yet, so I'll make my case and address the objections I expect.
1. LLY is growing like a startup at a $1T scale¶
- Revenue: Q2 2026 revenue was $22.97B, up 47.7% year over year and 16% sequentially. H1 revenue was up about 51%. Quarterly revenue is roughly 2.9x its Q1 2022 level.
- Earnings: H1 EPS was $16.20 versus $9.35, up about 73%. H1 net income was $14.5B versus $8.4B.
- Margins: Q2 gross margin was 85.8%, the highest in the six-quarter series. TTM gross margin is 83.4%.
- Cash: H1 operating cash flow was $16.0B versus $4.75B a year earlier, about 3.4x. In Q2, operating cash flow ran roughly 1.5x net income, so earnings quality looks fine.
- Demand: Walmart is extending free coverage of Mounjaro to employees, which points to broader employer coverage. The Taltz/Zepbound biomarker synergy story suggests LLY is more than a one-molecule thesis.
2. The tape says institutions are buying¶
- LLY rose 3.62% to 1208.74 on a day Nasdaq fell about 1.65%, on about 1.4x average volume (provisional).
- That is a new 30-day closing high. Price sits above the 10 EMA (1176), 50 SMA (1177) and 200 SMA (1076), and the weekly and monthly SuperTrends are both up.
- RSI is 60.4, so it isn't overbought. MACD has been positive since 10-07.
- The stock is up about 42% from the April 29 low of 848.53. The August and September closing lows (1114.08 and 1115.70) held almost exactly, which looks like a base.
- Beta is 0.45. In a hot-inflation, rising-yield, tech-sell-off tape, LLY behaved like a defensive compounder.
3. Rebuttals to the bear's likely arguments¶
"It's expensive: 40.6x trailing, 97x P/FCF, 1% FCF yield." Trailing multiples flatter slower growers and punish hypergrowth. Annualized H1 GAAP EPS of $32.40 puts the stock at about 37x, for a company growing revenue about 48% and EPS in the mid-20s or better. The vendor's forward P/E is 25.5x and PEG is 1.13. I won't lean on the $47.48 forward EPS, since it's probably a next-year, possibly non-GAAP figure. Even without it, the multiple is defensible. The low FCF conversion (about 41% of net income) coexists with operating cash flow growing about 3.4x. Q2 investing outflow was about $15.4B, so the likely story is reinvestment for growth, though capex isn't broken out.
"Q2 net margin fell to 30.9% from 37.4%. Profit isn't keeping up with revenue." Gross margin rose in Q2, so the squeeze is below the gross line. Net margin has been lumpy for a year: 21.7%, 36.4%, 31.7%, ~34.4%, 37.4%, 30.9%. The last four quarters average about 33.6%, in line with the vendor's 33.5% TTM figure. Acquired IPR&D charges are one plausible cause, and they have hit prior quarters (Q3 2023, Q3 2024). That is a hypothesis to check in the 10-Q, not a confirmed fact. Net income and EPS still grew about 25% and 26% year over year against a 36.4% net-margin comp.
"Liabilities jumped $23B in one quarter." It's a real step-up and I'm not hiding from it. But the context matters. Implied debt is about $55B against cash of $9B, so net debt is about $46B, or about 1.1x TTM EBITDA of $41.7B. The current ratio is 1.355, and equity has grown from about $14.3B to $33.9B in under two years. The 162% debt/equity looks scary mainly because buybacks and dividends shrink the equity base. The 102% ROE has the same cause. Non-current assets rose about $15.9B, which looks like capacity or deals. What it bought matters, and I'll concede the 10-Q is the place to confirm.
"Insiders are selling and the Endowment dumped stock." Officers sold about $18.8M over three months, under 0.002% of a $1.077T market cap. Seven insiders, including the CEO and CFO, bought at $634–$692 in August 2025, and those buys are up 75–90%. The Endowment sold about $3.63B between September 2025 and May 2026, and the stock still went much higher. It has sold only $15.8M since January 2026 and nothing since May.
"Fed hike risk and higher-for-longer rates will crush the multiple." This is the bear's best macro argument. Polymarket puts a hike on Oct 29 at 28%, up 13pp in a week, and 97% for no cuts in 2026. But the same market prices recession at only 8%, so demand for medicines isn't under threat. LLY rallied on the day yields rose and tech sold off, which is the opposite of how a fragile long-duration stock trades. With a beta of 0.45, LLY is where capital goes when rate fear hits the AI trade.
"Competition: Viking's oral pill is in Phase 3 and Roche has an RNAi candidate." Both are years from commercial impact, and LLY is growing about 50% with Novo in the market. Walmart's coverage includes Ozempic as well as Mounjaro, which signals the category is expanding, not that LLY is losing share. Retatrutide odds of 3% for 2026 approval mean it is pipeline optionality, not a 2026 catalyst, and nothing in the price depends on it.
"Technically it's stretched." I partly agree, and the bull case doesn't need the next candle to cooperate: - The daily z-score is +2.26. - The close is 4.60 above the upper Bollinger Band. - ADX is only 20. - The daily SuperTrend is still down, with its line at 1217.65, just 0.73% above the close. - OBV is about 2M below its September peak.
That points to a possible pullback, not a trend break, and the support ladder is clear: 1204, then the 1176–1177 EMA/SMA cluster, then 1168.60, then 1142–1143. The weekly stop sits 23% below price, and the first line of damage is a close below about 1115. A daily close above 1217.65 on rising volume would put all three SuperTrend tiers in agreement. After that, the 1230–1255 zone and the 1280.34 closing high (1292.65 intraday) are the targets, only about 6–7% away.
"Retail is euphoric, so it's crowded." I agree the StockTwits read is mostly noise. It covers one afternoon, much of it is promotional or about other tickers, and the "1,290 tomorrow" calls are meaningless. I'm leaning on cash flow, price behavior against the market, and volume, not retail posts.
4. Risks I'm watching¶
- Q3 earnings: The date is unconfirmed (one social post says Oct 29, which would coincide with the FOMC). J&J fell after a beat and raise, so the bar is high.
- The Q2 below-the-line costs and the liability jump need explaining in the filings.
- Gap risk: LLY has gapped 10.3%, 9.8%, 7.1% and 4.9% in 2026, on 6–8M shares. These moves dwarf the 34-point ATR, so size positions with that in mind.
5. Bottom line¶
Revenue is growing about 48% to 51%, gross margins are above 83%, operating cash flow is accelerating, leverage is modest at roughly 1.1x net debt/EBITDA, the base held at 1114–1115, and institutions bought the stock on a day the market sold off. At about 37x annualized GAAP earnings, I think that is a fair price for the growth.
My preferred approach is to accumulate on pullbacks toward the 1176–1177 cluster, add on a volume-confirmed daily close above 1217.65, and treat a close below about 1115 as the thesis-weakening line.
Bear, what's your best case against this? Bull Analyst: # Bull Rebuttal for LLY, as of 2026-10-14
You landed some real punches. I'll concede what you've earned, then show that the thesis survives without those pieces.
1. What I'm conceding¶
- Valuation: You're right that 25.5x is just $1,208.74 / $47.48, and I can't keep the multiple while dropping the EPS. FY2026 would need $31.28 in H2, so $47.48 is a 2027 or adjusted number. I withdraw it as support. The PEG is also about 1.4 on Q2's 26% EPS growth.
- The 3.4x operating cash flow: It's a low-base effect, since H1'25 was $4.75B and 9M'25 was $13.6B. I'm dropping it.
- "Defensive compounder": Beta measures correlation, not the size of moves, and one day isn't a regime. What I'll keep is narrower: LLY has been uncorrelated with the AI/tech sell-off that is hurting everything else.
- Insider buys: The August 2025 buys are stale.
- Risk/reward at $1,208: The first target (+5.9%) against the 1115 line (−7.8%) is worse than 1:1. That is why my plan is staged. From 1176.5, the same levels give about +8.8% against −5.2%, roughly 1.7:1.
2. "37x on faith": what has to be true¶
My scenarios use ~892M flat shares and Q2's $22.97B as the base. They are illustrative arithmetic, not forecasts, and none of them uses the $47.48.
| Scenario | Sequential revenue growth | Net margin | NTM EPS | P/E at $1,208.74 |
|---|---|---|---|---|
| Stall | 0% | 30.9% (Q2) | ~$31.8 | 38.0x |
| Slow | 3% | 31% | ~$34.4 | 35.1x |
| Base | 5% | 32% | ~$37.3 | 32.4x |
| Your 9% run-rate | 9% | 33.5% (TTM) | ~$43.0 | 28.1x |
The risk is a revenue stall, not the multiple on today's numbers. Even if growth stops and Q2's compressed margin persists, the multiple is about 38x, versus 37x on annualized H1 EPS. Nothing in the data shows a stall. Quarterly revenue is up 2.9x since Q1 2022, and Q2 re-accelerated to +16% sequentially.
On growth measures: Q2 y/y EPS growth of +26% is measured against a 36.4% net-margin comp. H1'26 EPS of $16.20 against H2'25 of ~$13.59 (Q4 is derived) is +19% in six months, or about 42% annualized. The PEG is therefore somewhere between about 0.9 and 1.4, and neither end is a stretch for an 83% gross-margin business growing revenue 48%.
3. The $3.8B question¶
I can't explain it from this data, and I won't pretend to. I would check the 10-Q for acquired IPR&D, R&D, SG&A, other income/expense and tax. I would also check whether the +$15.9B of non-current assets is goodwill and intangibles (capitalized, so it amortizes) or PP&E (capacity).
I also don't need the benign answer to be true. You're right that Lilly buys pipeline regularly, so I'd underwrite a normalized margin of 31–33%, not 37%. Each net-margin point on Q2 revenue is about $230M, or about $0.26 a share. Even a partial reversion to the four-quarter average of 33.6% gives about $8.64 a quarter, and my table doesn't need that. A cost step that coincides with a $15.4B investing outflow looks more like a company buying growth than a margin that is eroding. That is still a hypothesis.
4. Cash and balance sheet¶
- Operating cash flow: You cite Q1 at 0.72x net income and Q2 at 1.5x. Together, H1 operating cash flow of $16.0B is 1.11x H1 net income of $14.5B, so the timing swing largely nets out.
- Current liabilities: You attribute the +$11.1B to accruals inflating operating cash flow. But Q2 financing was about +$8.4B, and short-term borrowing sits in current liabilities. A good part of the jump may therefore be debt, not payables. That is an inference, but it cuts against your reading.
- Leverage stress test: I'll stop leaning on the vendor's EBITDA. Net debt of about $46B against TTM net income of $26.7B, which is already after interest, tax and D&A, is 1.7x. That is not an alarming number.
- The "gap": TTM FCF of $11.07B covers your $6.3B dividend estimate about 1.75x. The shortfall you describe comes from investing outflows beyond capex, which are discretionary and in part acquisitions.
- Buybacks: I agree buybacks at 31.8x book are unconfirmed. Equity rose $2.7B against $7.1B of net income, and after about $1.6B of dividends, ~$2.8B is unexplained, up from ~$1.15B in Q1. That could be repurchases or other equity items, and the 10-Q will say which.
5. The tape¶
- Volume: Comparing 3.16M shares to the 6–8M gap sessions is the wrong baseline, since those were catalyst days. Against the ~2.2M average it's 1.4x, and it came on a day Nasdaq fell 1.65%.
- OBV: At 347.87M it is 0.6% below the 349.87M peak. A single up day on above-average volume (~2M shares) closes that gap.
- The SuperTrend line: The high of 1216.71 missed 1217.65 by 0.08% with an ATR of 34. That's a near miss, not a rejection. I agree it hasn't flipped, and your trigger #3 is the same as mine.
- "Back to late June": Price is in the same 1200–1236 area, but TTM revenue is up about 10% since then ($72.3B to $79.7B) and TTM EPS is up about 6% ($28.14 to $29.79). The trailing P/E compressed from roughly 43x to 40.6x while price went sideways. That is a time correction, not a price correction.
- The drawdowns: The 13% pullback and the slide to 848.53 happened and I don't dispute them. The stock is now 42% above that low, while revenue growth ran at +55.5% and +47.7%.
6. Macro and policy¶
Your macro point is the best bear argument, and I grant it. Low recession odds plus hot inflation means a hawkish Fed, and that is a multiple risk. But 97% no-cuts is already the baseline, so the incremental risk is the 28% hike odds. This week's hawkish repricing coincided with LLY outperforming. That's one day, but it's the relevant day.
On long duration, cash flows are not far out. Operating cash flow was $16.0B in H1 and TTM FCF is $11.07B.
The MFN/tariff gap is real and I can't size it. But Q2's 85.8% gross margin and +47.7% revenue came inside today's policy regime. It is a sector-wide risk that argues for sizing, not for avoiding the fastest-growing large-cap in the tape.
7. Insiders¶
The four officer sales were 2,000–6,500 shares each. The CEO and CFO aren't among them. The CEO's February grant alone ($40.7M) was more than twice the combined $18.8M of sales. You're right that holdings aren't in the data, so I treat this as noise, not signal.
The Endowment can return, and I can't rule that out. But it sold nothing while the stock ran to 1280 in August, which is weak evidence the program has paused.
8. Why I wouldn't trim¶
You concede the 2026 tail has been up: all four gaps (+10.3%, +9.8%, +7.1%, +4.9%) were upward. A holder who trims at $1,208 is selling exposure to the one tail both of us agree is real.
Our plans mostly overlap. We both want 1176–1177 or a confirmed close above 1217.65. We differ on holders: you trim and I keep a core position. I'd manage risk with the 1115 line, not with the entry price.
9. What would make me wrong¶
- A Q3 print with sequential revenue growth below ~3% (the stall scenario).
- A 10-Q showing a recurring cost base that pushes normalized net margin below ~30%.
- A close below ~1115 on rising volume.
- Q3 EPS below the $7.94 Q2 print.
- A hike or hawkish guidance on Oct 29 that breaks 1176 on volume. That would be a reason to cut size, even if the earnings thesis is intact.
Bottom line¶
I've given up the $47.48 forward EPS, the 3.4x operating cash flow and the "defensive" label, and the thesis still holds. Revenue is growing about 48%, H1 operating cash flow was 1.1x net income, leverage is about 1.7x net debt/net income even on a harsh measure, and the stock has gone sideways for four months while earnings grew. At $1,208 I would not chase. I'd hold a core position, add on pullbacks to 1176–1177, and add again on a volume-confirmed close above 1217.65. Bull Analyst: # Bull Closing Argument for LLY, as of 2026-10-14
You asked one direct question, so I'll answer it first. Then I'll list where you're right and make my case on the two points where I think you're wrong: what the capex means, and whether a holder should trim.
1. Which Q3 result says 38x was too much?¶
Fair hit. My tripwires defined a stall, but the price needs the base case. Here is the corrected map, using about 893M shares (Q2 net income of $7.095B divided by $7.94 EPS):
| Q3 outcome | Sequential revenue | Net margin | Q3 EPS | My action |
|---|---|---|---|---|
| Stall | 0% | 30.9% | ~$7.94 | Base case is wrong, and 38x is unsupported |
| Slow | +3% | 31% | ~$8.21 | Hold the core, stop adding |
| Base | +5% | 32% | ~$8.64 | Thesis on track |
| Run-rate | +9% | 33.5% | ~$9.39 | Add |
Your $8.26 line falls between Slow and Base, and I accept it. If Q3 EPS comes in below $8.26 (Q1's print), LLY will have made no sequential EPS progress in two quarters. I would stop adding and cut to a starter position. At or below $7.94, I'm wrong on the base case.
Judge the print sequentially, because year-over-year headlines will flatter it. Even a pure stall quarter shows revenue up about 30.5% ($22.97B vs $17.60B) and EPS up about 28% ($7.94 vs $6.21). Q3'25 is a soft comp, with a 31.7% net margin.
2. What I concede¶
- PEG: I drop the 0.9. On your year-over-year convention the base case is about 1.3 and the run-rate case about 0.6. I have no peer multiples in this dataset, so I can't call 1.3 cheap. I can call it fair for a base case that already assumes a sharp deceleration.
- The multiple is the swing factor. A stall at 30x on $31.8 is about $954, or −21%. That is roughly the slide LLY already took into April and then recovered 42% from. It's the loss I size for, and it's why I won't hold a full position at $1,208.
- FCF definition: You're right that FCF is operating cash flow minus capex. I was answering your $3.3B gap between operating cash flow and total investing, which does include non-capex items. But your derived TTM capex of at least ~$13.8B (≥17% of revenue) is a real catch. I stop calling that spending discretionary.
- Current liabilities: Whether the +$11.1B is payables or short-term debt is unresolved. That's why I lean on H1 operating cash flow (1.11x net income), not Q2. Debt maturities are a 10-Q item for both of us.
- Insiders: The CEO grant is compensation, and the sales are noise.
- "Institutions are buying": I withdraw it, since we have no flow data. What I keep is narrower: 1.4x average volume says the move wasn't thin.
3. What the capex buys¶
Capex is where I disagree with your conclusion, not your arithmetic.
- Run-rate growth: Q2'26 revenue annualizes to about $91.9B, against $62.2B for Q2'25. That is about $29.7B of added run-rate revenue in four quarters, against TTM capex of at least $13.8B, at an ~84% gross margin. This is rough and not an ROIC calculation, but the spending is visibly producing revenue.
- The "decade of paydown" is a static view. It divides $46B of net debt by $4.7B of FCF after dividends, which measures an investment trough. Using your own "even if Q4'25 was zero" method, TTM operating cash flow is at least ~$24.9B. Net debt is therefore no more than about 1.9x TTM operating cash flow.
- Capex is a lever. In the stall case you fear, the company paces spending to demand, and FCF rises. That is reasoning, not data, but it makes the stall row less dire for cash than for the multiple.
4. The gap argument¶
I'll grant two things. The Feb 4 up-gap was followed by a slide of 20% or more to 848.53, so up-gaps don't insulate anyone. And the J&J beat-and-fall is a real precedent. Here is why I still don't trim:
- The losses came as grinds. The slide to April and the 13% drop from 08-19 to 09-11 both happened without a large down-gap. All four single-day moves above 4.9% in our data were up. Stops and a 1115 line manage grinds, and sizing manages gaps. I'd size the core so a 10% gap (about $121 a share) is tolerable. The largest gap-down analog opens near 1,084, just above the 200 SMA at 1,075.89.
- Your rebuy has the same execution problem. An up-gap of +4.9% to +10.3% opens at about 1,268–1,333, above the 1,280 closing high. Trimming ahead of the print is a bet on the sign of the gap. I have no edge on the sign either. My prior leans up, from a four-for-four record and a +16% sequential quarter, and yours leans down. Both are priors on a small sample.
- Setups: You're right that the Apr 30 and Aug 5 gaps launched from lows. The data doesn't characterize the Feb 4 and Jun 26 launches. After August the stock also gave back the whole post-Q2 run, so expectations are lower than they were at 1,280.
If a 10% gap is bigger than a holder can tolerate, trimming to size is reasonable. That is a sizing call, not a view against LLY.
5. Policy and the tape¶
Midterms are about three weeks out, and the data is silent on MFN and tariffs. I can't size that risk, and it's sector-wide, so it argues for sizing and not for avoidance. The rotation could reverse, and the +3.6% day isn't my thesis. I use the tape only for entries and risk lines.
Bottom line¶
We agree on most of it. Neither of us chases $1,208.74. We both want 1,176–1,177 or a volume-confirmed close above 1,217.65. We both think revenue momentum is real and solvency isn't the fight. The remaining disagreement is whether to hold a sized core through Oct 28–29 or trim into it.
My plan: - Hold a core position sized for a ~10% gap. - Add at 1,176–1,177, or on a daily close above 1,217.65 with OBV above 349.9M and ADX above 25. - Cut to a starter if Q3 EPS is below $8.26, or if the 10-Q shows a recurring cost base that pushes net margin below 30% or short-dated debt that needs refinancing. - Exit the incremental adds on a close below ~1,115 on rising volume, or at Q3 EPS of $7.94 or lower.
At 37–38x GAAP, LLY is a fair price for a business growing revenue about 48% with an 83–86% gross margin. It's not a free one. I'd rather own the growth with a defined exit than sell a name whose only large single-day moves this year have all gone up. Bull Analyst: # Bull Final Rebuttal for LLY, as of 2026-10-14
Your closing moved you from "don't own it" to "own less, buy lower," and I think that is now the whole debate. Three questions are left: what the price is built on, whether my exit works, and trim versus hold. I'll concede what you've earned and mark where I still disagree.
1. The Street's number¶
You're right that "on track" and "stock goes up" are different statements. I withdrew $47.48 as support, but the market didn't withdraw it from the price. Your $41 reproduces: $114.6B of CY2027 revenue × 32% ÷ 893M shares.
The same arithmetic shows what $47.48 would take. If it is GAAP, then on my base revenue path it needs a 37.0% net margin ($42.4B on $114.6B). Lilly printed 37.4% in Q1'26 and 36.4% in Q2'25, which is two of the last five quarters. So the question is again whether Q2's cost step repeats. If $47.48 is non-GAAP, the gap to my $41 is probably that same cost layer.
On the size of that layer, $3.8B is the harshest framing, because it holds every below-gross cost flat at Q1 dollars while revenue rises 16%. Instead, scale Q1's gross-profit-to-net-income gap (44.5% of revenue) to Q2 revenue. That leaves an excess of about $2.4B (~$2.7 a share) instead of $3.8B (~$4.3). The truth sits between the two, because opex isn't fully variable. Acquired IPR&D, launch spending and capacity ramp are all hypotheses the dataset can't separate.
My table already prices the step as permanent, with 30.9%, 31% and 32% margins. If it is one-time, every row is understated. Your downside needs two things together: the step is recurring, and the Street figure is a GAAP number that assumed it wouldn't be.
2. The break-even table¶
Your arithmetic is right, and I have two objections. First, it holds 30x and 35x across all four rows. By your own logic that multiples fall when growth stalls, they shouldn't fall as far when growth holds. With multiples that move with the scenario:
| Row | NTM EPS | Multiple | Price | vs $1,208.74 |
|---|---|---|---|---|
| Stall | $31.8 | 28x | $890 | −26% |
| Slow | $34.4 | 31x | $1,066 | −12% |
| Base | $37.3 | 33x | $1,231 | +2% |
| Run-rate | $43.0 | 36x | $1,548 | +28% |
Second, the rows aren't equally likely. My run-rate row is the 9% a quarter you told me to underwrite in your opening. The trailing four-quarter sequential average is 10.3% (+13.1, +9.6 derived, +2.6, +16.0). My base row is half of that. No quarter in the window stalled, and the weakest was +2.6%.
The payoff is wide, from −26% to +28%. I agree that is a sizing problem, and I adopt your standard: size to the stall row, not to a 10% gap. It also answers "+5.9% versus −21%." Those are different horizons, and the 12-month counterpart of +5.9% is the +28% row.
3. Capex¶
I accept that this is a growth-multiple bet. Your timing point cuts my way, though. If TTM capex of at least $13.8B (17% or more of revenue) is building capacity for 2027–28, management is funding demand well above my 5% base. That is a signal, not proof. The 1% FCF yield is also measured after that spending.
4. The exit¶
I'll fix the level. The trigger is a close below 1,114.08, the range's lowest close, not a loose "~1,115." Both tests (08-04 and 09-11) held it, as designed. Yes, that tolerates a 13% drawdown from the 08-19 high, which is the price of not being whipsawed in a range. The tiers:
- Close below 1,114.08: cancel adds and cut to a starter.
- Close below the 200 SMA (1,075.89, −11%): exit.
- Q3 EPS rule: you're right that it fires after the gap, so sizing is the only gap protection.
5. Trim versus hold¶
You're right in principle that cost basis shouldn't matter. If my position is above what the −26% stall row allows, I should trim now, whatever the calendar says. That is a weight rule, not an event rule.
I still disagree with trimming because Oct 29 is near. Trim-and-rebuy earns about 2.7% on the slice if price retraces to 1,177 and the print doesn't gap. If it gaps up like the three 2026 gaps that line up with Lilly's usual reporting windows (Feb 4 +10.3%, Apr 30 +9.8%, Aug 5 +4.9%, which is my inference since the tools don't label them), the slice misses 4.9–10.3% and the rebuy sits above 1,268. You said you aren't short because the up-tail is real. A trim ahead of the print is short that tail on that slice.
The setups do differ. The stock enters this print 8.3% above the September low after a rotation day, and J&J's beat-and-fall is a real precedent. Those argue for modest expectations, not for leaving.
6. The open item¶
I agree that reading the Q2 10-Q is the highest-value action available. The gap is in our toolset, not in the filing. I'd make the position conditional on it:
- Cost step is IPR&D or other non-recurring, and debt is term and fixed-rate: hold the core and add at 1,176–1,177.
- Cost step is recurring opex at a structural ~31% margin: cut to a starter, since a GAAP $47.48 would then be at risk.
- Meaningful short-dated debt: size down before Oct 29, because the FOMC carries a 28% hike probability.
Bottom line¶
We agree not to chase $1,208.74. The remaining difference is whether to trim because of the calendar or because of weight. I say weight.
Plan: - Hold a core sized to survive −26%. - Add at 1,176–1,177, or on a daily close above 1,217.65 with OBV above 349.9M and ADX above 25. - Cancel adds and cut to a starter on a close below 1,114.08, or on Q3 EPS below $8.26. Exit on a close below 1,075.89, or on Q3 EPS at or below $7.94.
The bullish case rests on three things: revenue has averaged about 10% sequential growth while my base case assumes 5%, I've already priced the cost step as permanent, and every large single-day move this year has been up. At 37–38x GAAP this is a fair price for a rare growth profile, not a bargain. I would own it with a defined exit and a size I can survive being wrong at, not sell it on a calendar date. Bull Analyst: # Bull Final Rebuttal for LLY, as of 2026-10-14
The disagreement is now narrow. If I accept −26% as my sizing standard, your trim follows. I think I over-conceded that standard last round, and I'll say where. First, what you've earned.
1. What I concede¶
- My margin claim was wrong. I said Lilly printed 37% "in two of the last five quarters." Q2'25 was 36.4%, which is below 37.0%. Only Q1'26 cleared it, and the five-quarter average is 34.2%. If $47.48 is GAAP and comes via margin, it has little support. The revenue route is the plausible one: about $126B in CY2027 at 33.6%, roughly repeating last year's dollar adds. That is reachable but has no cushion.
- The multiple I should quote is higher than 25.5x. On my own base row, the GAAP multiple is 29.4x CY2027 EPS and 32.4x NTM EPS.
- The base row is roughly flat. It returns +2% over 12 months. Your weights give −2% to +4%, and moving five points of weight from stall to run-rate adds about 2.7 points. The weights are judgment calls and we have no peer multiples. A reasonable range is about −2% to +7%, which is fair, not cheap. That is why I won't add at $1,208.
- The gap tail is weakening. The earnings-aligned gaps shrank from +10.3% to +9.8% to +4.9%, and August round-tripped completely. I withdraw "every large move has been up" as a comfort. It describes a small sample.
2. Where I think you're wrong¶
The −26% row isn't the loss a managed position takes. It is an unmanaged 12-month outcome, and it passes through my exits. Measured from today, which is the right basis if cost basis is irrelevant, a close below 1,114.08 is −7.8% and a close below the 200 SMA (1,075.89) is −11.0%. The 13% "tolerated drawdown" is measured from the August high, which no new buyer paid.
What exits can't handle is a print-day gap. That is the right sizing standard: exit-managed loss plus gap slippage. I have no down-gap sample, and a stall print on a ~40x name could exceed the 10.3% up-gap. So I'll use 15%:
| Loss standard | Weight vs. 10% standard | Trim from a 10%-sized holder |
|---|---|---|
| 10% | 100% | 0% |
| 15% | 67% | about one-third |
| 26% | 38% | about 60% |
I'll meet you partway. Anyone sized to the old 10% standard should trim about a third. That is a weight rule, not a calendar rule, and it isn't an exit.
Q1's +2.6% isn't a precedent for the Slow row. Q1 and Q2 together average 9.1% a quarter ($19.29B to $22.97B). Q1 is also seasonally soft. My recollection is that Q4'24 revenue was about $13.5B, which would make Q1'25 roughly −6% sequentially. That figure is not in our dataset, so verify it. Q3'25 was +13.1%. Q1'26's +2.6% is also derived from a vendor TTM subtraction, so it carries some error. I can't rule out that Q2's +16% included timing effects I can't see. Still, a +3% Q3 would be a sharp break from this pattern, not a repeat of it.
The run-rate row is a deceleration. Nine percent a quarter is about +41% y/y by Q2'27, against +47.7% today. The dollar adds are larger ($9.5B vs. $7.4B) because the base is larger. You argued that TTM capex of at least $13.8B is building for 2027–28 demand. If so, management is funding demand above my 5% base. That is an inference, not proof.
3. Trim vs. hold¶
We both said we have no edge on the sign of the next gap. Then a trim is variance reduction, which is a sizing decision, and I agree it can be right. We differ on how much: a third or 60%. That depends on a loss budget, which is a fact about the holder and not about LLY. Weight should drive the decision, not the date of the print.
4. Final plan¶
- Don't buy $1,208.74.
- Size the core to a ~15% adverse print. Trim now if above that weight.
- Add at 1,176–1,177, or on a daily close above 1,217.65 with OBV above 349.9M and ADX above 25.
- Cancel adds and cut to a starter on a close below 1,114.08, on Q3 EPS below $8.26, or if guidance can't support something near the Street's forward number (once we know whether it is GAAP).
- Exit on a close below 1,075.89 or Q3 EPS at or below $7.94.
- 10-Q branches: a non-recurring cost step with term, fixed-rate debt means hold and add. A recurring cost step at a ~31% margin means a starter. Short-dated debt means size down before Oct 29 (date unconfirmed).
Bottom line¶
We agree LLY is a rare growth business at a fair-not-cheap price, and that neither of us chases it. The debate comes down to a one-third trim versus a 60% trim, set by a loss budget. The unresolved item is the Q2 cost step. I couldn't read the 10-Q with these tools, and whoever does should move the position.
What would make me wrong: Q3 EPS at or below $7.94, a recurring cost base that puts normalized net margin below ~30%, short-dated debt that needs refinancing into a hawkish Fed, or a volume-confirmed close below 1,114.08.
Bear Researcher¶
Bear Analyst: # Bear Case for LLY (Eli Lilly and Company), as of 2026-10-14
You've made a strong opener, and I'll start with what I concede. This is an exceptional business, with revenue up 47.7% and gross margin at 85.8%. My case is narrower. At $1,208.74, after a 3.6% one-day pop, the price assumes the clean version of the story. The data in front of us shows that Q2 wasn't clean, and the tape isn't confirming the move.
1. Your valuation defense contradicts itself¶
You cite a 25.5x forward P/E and a 1.13 PEG, then say you won't lean on the $47.48 forward EPS. But 25.5x is $1,208.74 / $47.48, so you can't keep the multiple and drop the earnings.
That EPS is also 46% above the $32.40 run-rate you annualized. If it were FY2026, H2 would need $31.28, about $15.6 a quarter, against $7.94 in Q2. So it's a 2027 or adjusted figure, and the 25.5x is a multiple on earnings more than a year out.
That leaves your own 37x GAAP number. You justify it with EPS growth "in the mid-20s or better." Q2 EPS growth was 26%, so the PEG is about 1.4, not 1.13.
2. The 73% H1 EPS growth is a comp artifact, and the trend is decelerating¶
- Q1'25 had a 21.7% net margin, a depressed base. Q1'26 EPS growth was about +170%, and Q2'26 was +26%.
- Q2 EPS fell sequentially, from $8.26 to $7.94, on revenue up 16%. Gross profit rose about $3.5B and net income fell about $0.3B, so roughly $3.8B of extra cost landed below the gross line in one quarter. Neither of us knows what it was.
- IPR&D is your hypothesis. Your own examples (Q3'23, Q3'24, now possibly Q2'26) show these charges recur every year or two. A business that regularly pays to buy pipeline doesn't get to call that one-time. If the $15.9B jump in non-current assets was a deal, it was either expensed, which hits the P&L, or capitalized, which will amortize. Neither is free.
- You call net margin "lumpy" (21.7 → 36.4 → 31.7 → 34.4 → 37.4 → 30.9). On an 85% gross-margin business, a 6-point quarterly swing is an earnings-visibility problem. At 37x, you're paying for predictability.
- The 16% sequential revenue growth followed a derived 2.6% in Q1. The two-quarter average is about 9% a quarter, which is the run-rate to underwrite. The 85.8% gross margin was also 81.9% one quarter earlier, so it's a peak, not a baseline.
3. Your best cash and balance sheet numbers are the thinnest¶
- The 3.4x operating cash flow jump is a low-base effect. H1'25 was $4.75B, but 9M'25 was $13.6B, so Q3'25 alone was about $8.8B. Q1'26 operating cash flow was 0.72x net income. The Q2 1.5x ratio coincided with an $11.1B rise in current liabilities. Timing of accruals and payables can inflate operating cash flow and then reverse. That is a hypothesis to check, but it's at least as plausible as your "earnings quality looks fine."
- LLY is outspending its cash. H1 operating cash flow of $16.0B against investing of $19.3B leaves a $3.3B gap before dividends. My estimate for annual dividends is about $6.3B ($7.1 × ~891M shares), which leaves TTM FCF of $11.07B with only about $4.7B after dividends. The difference is being borrowed, with financing at +$5.0B in H1 and +$8.4B in Q2. "Reinvestment for growth" is your guess, and you admitted capex isn't broken out.
- The 1.1x leverage rests on a shaky input. It uses a vendor EBITDA of $41.7B (52.3% margin), and the fundamentals report couldn't reconcile the vendor's 54.2% operating margin with a 30.9–33.5% net margin. Liabilities rose about $23B in one quarter, and equity/assets fell from 26.8% to 23.8%. Your buyback explanation for the equity base is an inference. If true, it means borrowing to repurchase stock at 31.8x book and a 1% FCF yield, which isn't reassuring when the Fed is leaning toward hiking.
4. "Defensive compounder" rests on one day¶
Beta of 0.45 measures correlation with the market, not the size of the moves. LLY's own history says it isn't defensive:
- Gaps of +10.3%, +9.8%, +7.1% and +4.9% in 2026, and a 2.85% ATR.
- A slide of more than 20% from the ~1100s to 848.53 by April.
- A 13% drop from the 1280.34 close on 08-19 to 1115.70 on 09-11, in under four weeks. That came right after the best-looking quarter in the data.
- Valuation of 13.5x sales, 31.8x book and about 97x P/FCF is not a defensive profile.
The rotation story is also fragile. Barron's and StockTwits attribute the move to money leaving AI and tech. The same news feed has an undated "tech rebounded as AI-trade jitters eased" headline, and rotation flows reverse. Zacks' "fell more than broader market" headline shows LLY doesn't always hold up on down days either.
5. The tape doesn't say "institutions are buying"¶
- No flow data was provided. The only evidence is price and a provisional 3.16M-share volume, which is just under half of the smallest 2026 gap session (6.45M).
- The 1216.71 high failed 0.94 below the daily SuperTrend line at 1217.65, leaving an upper wick. OBV is still about 2M below its 09-28 peak while price is higher, and ADX has slid from 31.0 to 20.1. The daily z-score is +2.26 and the close is 4.60 above the upper band.
- A "new 30-day closing high" sits inside a three-and-a-half-month range and is still 5.6% below the 08-19 close. Price is roughly back where it was in late June, after a quarter in which revenue grew 16%.
- Your own levels give the risk/reward. Your first target of 1280.34 is +5.9%, and your thesis-weakening line of 1115 is −7.8%, which is worse than 1:1. Your plan is to buy 1176–1177, so you're conceding that 1208 isn't the price to pay.
6. The macro rebuttal misses the point¶
Hike odds are 28% (+13pp in a week) and 97% say no cuts in 2026. You answer that recession odds are only 8%. But low recession odds plus hot inflation is exactly what produces a hawkish Fed. Nobody is arguing that demand for medicine collapses. The argument is about the multiple: a ~1% FCF yield and a 0.59% dividend make this a long-duration asset, with oil near $103 adding to the inflation risk. One outperforming day on a tech sell-off doesn't show the stock is immune to rates.
The data is also silent on drug pricing, MFN and tariff policy, with the midterms about three weeks away. The report calls that a gap, not a clean bill of health. A record 85.8% gross margin on a drug class that large employers are now covering at no cost to employees is the kind of margin that attracts policy attention. The Walmart headline gives no pricing details.
7. Insiders and the Endowment¶
- The August 2025 buys at $634–$692 are 14 months stale. Buying at $650 says nothing about buying at $1,200.
- The officer sales were at $1,150–$1,190, where the stock is today, and there have been no buys since. Comparing them to market cap is the wrong denominator, since holdings aren't in the data.
- The Endowment's "nothing since May" is a pause. It sold roughly 292K shares on 7 Jan at about $1,102, and its round-number blocks look programmatic. A 10%+ holder who has sold into prior rallies can return at $1,200.
8. The next catalysts are two-sided, and the pipeline offers no cushion¶
Next up are the Oct 28–29 FOMC meeting and Q3 earnings, reportedly Oct 29 but unconfirmed. J&J just fell after a beat and raise. Retatrutide has a 3% chance of approval this year, so nothing in the pipeline offsets a disappointment.
You also say "nothing in the price depends on" the next-generation pipeline. But the forward multiple you cited needs about 46% EPS growth, and that has to come from somewhere. Viking and Roche are years away, but a $1.08T market cap is also a bet on years from now.
Bottom line¶
I'm not calling LLY a short, because all four 2026 gaps were up and that tail is real. My view is don't initiate or add at $1,208. Anyone holding should treat this strength as a place to trim or protect gains. My entry zone is the pullback levels you named, 1176–1177 or lower, or after the FOMC and earnings events clear.
I would change my mind if: 1. The 10-Q shows the Q2 cost step-up was identifiable and non-recurring, and the debt is clean. 2. Q3 shows net margin back in the mid-30s with EPS clearly above $8.26. 3. Price makes a daily close above 1217.65 with OBV above 349.9M and ADX above 25.
My question for you is what explains the $3.8B of added cost below the gross line. Until you can answer that from the filings, 37x is a price paid on faith. Bear Analyst: # Bear Rebuttal for LLY, as of 2026-10-14
You gave up the $47.48 forward EPS, the 3.4x operating cash flow, the "defensive" label, the stale insider buys and the 1:1 risk/reward at $1,208. I re-ran your table and the arithmetic reproduces. So the question is what the thesis looks like without those pieces.
1. Where we agree¶
- Revenue isn't my fight. Sequential growth over the last four quarters was +13.1%, +9.6% (Q4 derived), +2.6% and +16.0%, averaging about 10%. It's lumpy, but strong.
- Solvency isn't my fight. 1.7x net debt to TTM net income is not alarming.
- Neither of us wants to buy $1,208.74. We both want 1176–1177, or a volume-confirmed close above 1217.65.
We disagree on three things: what 37x pays for, whether the cash picture is as benign as you say, and whether a holder should trim into this move.
2. Your table shows the multiple but not what it pays for¶
Your PEG range of "0.9 to 1.4" mixes methods. The 0.9 end compounds a six-month sequential gain, which includes a derived Q4, into an annual rate. The convention is year over year, and Q2 was +26%. Here is your own table with the growth column added:
| Scenario | NTM EPS | Growth vs TTM $29.79 | P/E | P/E ÷ growth |
|---|---|---|---|---|
| Stall | $31.8 | +6.8% | 38.0x | 5.6 |
| Slow | $34.4 | +15.5% | 35.1x | 2.3 |
| Base | $37.3 | +25.2% | 32.4x | 1.3 |
| 9% run-rate | $43.0 | +44.3% | 28.1x | 0.6 |
- Only the top row gets the PEG under 1. It needs four straight quarters of 9% sequential growth, about +41% year over year by Q2'27, at a 33.5% margin.
- Your own base case is a deceleration. Revenue growth falls from 48% to about 21.5% year over year, and the price pays 32x for it.
- The table holds the multiple constant, and that's the variable that breaks. A stock that goes from +48% revenue growth to flat doesn't keep 38x. On the stall row, Q4 EPS growth is only about +8% ($7.94 vs the derived $7.38).
3. Your tripwires sit at or below Q2, but the price needs more than Q2¶
Four of your five "what makes me wrong" items are set at or below Q2: sequential revenue under 3%, normalized margin under 30% (Q2 was 30.9%), EPS under $7.94, and a close below 1115. The fifth is a Fed hike.
Your Slow row clears all of them. At 35x it gives a PEG of 2.3 and Q4 EPS growth of about +15%. A thesis that can only fail on results worse than Q2, at a price that needs better than Q2, is not very falsifiable. I'd want Q3 EPS above $8.26 with net margin at or above 33%.
You also still can't say what the $3.8B of added cost was. Your 31–33% normalization is reasonable arithmetic, but Q2 is the only data point on the current cost base. I'd rather read the 10-Q than assume 30.9% is the floor.
4. Cash: your correction doesn't hold¶
You said the gap between operating cash flow and free cash flow comes from "investing outflows beyond capex, which are discretionary and in part acquisitions." By definition, free cash flow is operating cash flow minus capex, and acquisitions don't enter it.
- Operating cash flow: Q3'25 was about $8.84B (13.59 − 4.75), Q1'26 was $5.33B, and Q2'26 was about $10.69B. That sums to about $24.9B.
- Capex: Against vendor TTM FCF of $11.07B, TTM capex is at least about $13.8B, even if Q4'25 operating cash flow was zero. That is roughly 17% or more of TTM revenue. This is my derivation, assuming vendor FCF is operating cash flow minus capex, since the capex row is blank in the statements.
- What it means: This is capacity spending, and your revenue ramp presumably needs it. It's not a discretionary lever.
- Debt paydown: After roughly $6.3B of dividends, about $4.7B of FCF remains against about $46B of net debt. On today's FCF, that is roughly a decade of paydown. The owner's cash yield is about 1.0%.
Current liabilities cut against you either way. Take your reading that part of the +$11.1B is short-term borrowing. Then a meaningful piece of the $23B liability jump is short-dated debt, to be refinanced into a market pricing a 28% chance of a hike and 97% odds of no cuts in 2026. Take my reading, that it's accruals and payables. Then Q2 operating cash flow was flattered and will reverse. I can't tell which until the 10-Q, but neither reading makes Q2 cash flow a clean signal.
5. The tape: $38B of market cap with no company news¶
- The move: +$42.23 on about 891M shares is about $38B of market cap in one session. The fundamentals report found no new filings, insider trades or company-level information this week. Barron's and StockTwits attribute the move to sector rotation.
- Rotation reverses: Your own feed includes a "tech rebounded as AI-trade jitters eased" headline.
- The price action isn't confirmed:
- The close is 4.60 above the upper Bollinger Band.
- The daily z-score is +2.26.
- ADX is 20.
- OBV is below its 09-28 peak.
- The daily SuperTrend hasn't flipped.
- Time correction: I accept that the trailing P/E went from 43.0x to 40.6x while price went sideways. But 40.6x isn't cheap.
- Retail euphoria: Retail posts cheer "new all time highs" and "$1.14 trillion." Price is 5.6% below the 08-19 close and market cap is about $1.077T. That enthusiasm is reacting to price, not data.
6. Why I'd still trim: the gap argument cuts both ways¶
All four 2026 gaps were up, and I agree that tail is real. But consider:
- Up-gaps didn't protect holders from drawdowns. The Feb 4 gap (+10.3%) falls inside the early-2026 stretch that took the stock from the 1100s to 848.53.
- The setups were different. The Apr 30 and Aug 5 gaps launched from the closing lows of the range, 848.53 and 1114.08. They also line up with Lilly's usual reporting calendar, which is my inference since the tools don't label them. This time the stock enters the print 8.3% above the September low, after a +3.6% day, with J&J's beat-and-fall as the precedent.
- Your stop can't be executed in the scenario it protects against. A gap down the size of the smallest or largest 2026 gap (4.9% to 10.3%) opens at about 1,150 to 1,084. That skips your 1176–1177 add zone and, at the high end, your 1115 line, before you can act. Your item #5, "cut size if a hike breaks 1176," is a decision you'd make after the gap.
The FOMC decision and the reported earnings date (unconfirmed) both land on Oct 29. I'm not trimming because the business is bad. I'm trimming because the exit you've drawn can't be used in the scenario you most need it for.
7. Smaller items¶
- Insiders: The CEO's $40.7M February grant is compensation, not a discretionary purchase, so it can't offset discretionary sales at $1,150–1,190. The sales are noise. My point is only that there has been no insider buying in 14 months.
- Policy: "Margins held inside today's regime" doesn't address a change of regime, with the midterms about three weeks out. The data is silent on MFN and tariffs, and 85.8% is the highest gross margin in the series.
- Endowment: Quiet since May is a pause, not a resolution.
Bottom line¶
We agree not to chase at $1,208. I would trim into strength ahead of Oct 28–29 and rebuy at 1176–1177 or lower, or after the events clear. I'm not short, because revenue momentum and the up-gap tail are real.
What would change my mind: 1. The 10-Q shows the Q2 cost step was identifiable and non-recurring, discloses capex, and shows the debt is term and fixed-rate, not short-dated. 2. Q3 shows sequential revenue growth of at least 5%, net margin of at least 33%, and EPS above $8.26. 3. A daily close above 1217.65 with OBV above 349.9M and ADX above 25.
You've set every tripwire at or below Q2, so which Q3 result would tell you that 38x on a no-growth quarter was too much? Bear Analyst: # Bear Closing for LLY, as of 2026-10-14
You answered the question I asked, and the revised tripwires ($8.26 to cut to a starter, $7.94 as proof the base case is wrong) are a real improvement. Here is where we've converged, and the places where I think the plan still doesn't hold.
1. Where we've converged¶
- Entry: Neither of us buys $1,208.74. We both want 1,176–1,177, or a close above 1,217.65 with OBV above 349.9M and ADX above 25.
- Revenue and solvency: Revenue momentum is real. I accept net debt of at most about 1.9x TTM operating cash flow. It leans on a Q2 operating cash flow that may be flattered, but I won't fight on it.
- Withdrawn points: You've dropped the $47.48 as support, the 3.4x operating cash flow, "defensive," "institutions are buying," and the 2025 insider buys. I've dropped the insider sales as a signal.
- What's left: What the price is built on, whether the exit works, and how much to hold into Oct 28–29.
2. Your tripwires are measured against your table, not the Street's¶
Your thresholds are built from Q1 and Q2 EPS. The stock trades against consensus and guidance, and our dataset has neither. J&J's beat-and-fall is the reminder.
The only expectations proxy we have is the vendor's $47.48 forward EPS behind the 25.5x. You withdrew it as support, but the market didn't withdraw it from the price. There are two readings:
- GAAP, calendar 2027: I ran your rows forward. The base row (+5% a quarter, 32% margin) gets to about $41, roughly 13% short. It takes about +7% a quarter at a 33% margin to reach roughly $46.
- Non-GAAP: The gap between that figure and GAAP is the same unexplained cost layer I keep asking about.
I don't know which reading is right, and neither do you. But your "base: thesis on track" row could be a miss against the Street. A thesis being on track and the stock going up are different statements.
3. Your table is also a break-even table¶
I assumed a trailing multiple a year out, on your NTM EPS. The 30x and 35x levels are illustrative, since the dataset has no peer multiples. Your own stall row already used 30x.
| Your row (NTM EPS) | Price at 30x | Price at 35x |
|---|---|---|
| Stall ($31.8) | $954 (−21%) | $1,113 (−8%) |
| Slow ($34.4) | $1,032 (−15%) | $1,204 (0%) |
| Base ($37.3) | $1,119 (−7%) | $1,306 (+8%) |
| Run-rate ($43.0) | $1,290 (+7%) | $1,505 (+25%) |
From a 40.6x trailing multiple today, a drift to 35x leaves slow flat and base up 8%. A drift to 30x loses money everywhere except the run-rate row. Growth is expected to halve from here, and a de-rating alongside that is not an exotic assumption. Your near-term upside is +5.9% to 1,280, against a −21% stall row.
4. Capex and the thin cash floor¶
- Timing mismatch: You credit $13.8B of TTM capex with $29.7B of added run-rate revenue. But today's revenue ramp runs on capacity built earlier. TTM capex is building for 2027–28 demand, so the comparison isn't an ROIC.
- "Capex is a lever": It's only free in the stall scenario, which is also the scenario where the multiple de-rates 20% or more. Even with capex at zero, TTM operating cash flow of at least about $24.9B is a 2.3% yield on $1.077T. Cash flow can't carry this valuation. It's a growth-multiple bet.
5. The exit doesn't fit the loss pattern you cite¶
- Grinds: You argue the losses came as grinds, which stops handle. But the 13% drawdown from 1280.34 ended at a 1115.70 close, which sits right on your "~1115" line. The pattern you describe would have ended at your exit without clearly triggering it.
- Real exposure: From today's entry the stop is −7.8%, but from the August high the tolerated drawdown is about 13%.
- Gaps: The Q3 EPS rule fires after the print, at roughly 1,084–1,150.
- Sizing: You say you size for a ~10% gap, but your own stall row is −21%, and the 200 SMA is at −11%. Those are different losses.
6. Trim versus hold¶
You're right that trimming is partly a bet on the gap's sign. I'm making a different argument:
- Price discipline: You'd add at 1,176–1,177 and not at 1,208. Holding a full core at 1,208 means valuing the shares above your own add price only because you already own them. Trimming a slice and re-adding at 1,177 applies the same discipline to old money as to new.
- Setups: Two of the four up-gaps (Apr 30, Aug 5) launched from range lows, and the dataset doesn't characterize the other two. This one would launch from 8.3% above the September low, after a +3.6% day driven by rotation with no company news. The sample is small, but the setups aren't equal.
- Size, not direction: You conceded that trimming to size is reasonable. The difference between us is that I size for the −21% case and you size for −10%.
7. The open item¶
The $3.8B of added cost below the gross line is still unexplained. The Q2 10-Q has been public for two months, and neither of us has read it. Until someone does, I'd cap exposure at a starter-sized position. I'd check:
- IPR&D, R&D, SG&A and tax lines.
- Whether the +$15.9B of non-current assets is goodwill and intangibles or PP&E.
- Debt maturities, and whether the debt is fixed-rate or short-dated, ahead of a Fed that has a 28% chance of hiking on Oct 29.
Bottom line¶
Position: Don't initiate or add at $1,208.74. Existing holders should trim into this strength to a size that survives the stall row, not just a 10% gap. Rebuy at 1,176–1,177 or lower, or after the FOMC, the Q3 print with guidance (date unconfirmed), and a read of the 10-Q. I'm not short: revenue is strong and every large single-day move this year has been up. But a fair price for a great business at 40.6x trailing, with a 1% FCF yield and an unexplained Q2 cost step, is not a margin of safety.
What would change my mind: 1. The 10-Q shows the Q2 cost step was non-recurring and the debt is term and fixed-rate. 2. Q3 shows sequential revenue growth of at least 5%, net margin of at least 33%, EPS above $8.26, and guidance that supports the Street's forward number. 3. A daily close above 1,217.65 with OBV above 349.9M and ADX above 25. Bear Analyst: # Bear Final Rebuttal for LLY, as of 2026-10-14
We now agree on almost everything except one decision: hold a sized core through Oct 28-29, or trim and rebuy lower. I'll concede what you've earned, then argue that your own numbers favor trimming.
1. What I concede¶
- Horizons: "+5.9% vs −21%" mixed a near-term technical target with a 12-month stall row. I withdraw it. The comparison belongs inside the table, from −26% to +28%.
- The 9% anchor: I did call the two-quarter average the "run-rate to underwrite," so your top row isn't invented. A trailing average isn't a forecast, but I set the anchor.
- The Q2 cost gap: $2.4B is a better estimate than $3.8B if costs scale with revenue. Either way it's at least $2.7 a share, and neither of us has identified it.
- The Street number is reachable: At a 33.6% margin, $47.48 needs about $126B of CY2027 revenue. That is about 7.2% a quarter for six quarters, which equals repeating last year's $7.4B of added quarterly revenue ($15.56B to $22.97B). It's a plausible outcome, not a fantasy.
2. Reachable isn't the same as cushioned¶
That 7.2% path is a repeat, with no acceleration needed and no slippage allowed. The margin route has less support. Only one of the last six quarters (Q1'26 at 37.4%) cleared 37%. The five-quarter average is 34.2% and the six-quarter average is 32.1%.
You say my downside needs two things together: a recurring cost step, and a GAAP Street figure. It doesn't. If $47.48 is non-GAAP, the GAAP forward multiple is not 25.5x. On your own base case it's 29.4x on $41.07 (CY2027) or 32.4x on $37.3 (NTM), and your valuation case is GAAP. If it's GAAP, it needs best-quarter margins. The gap between $41 and $47.48 is 16% of the share price, and we can't resolve it with this data.
Three of the last six quarters printed margins at or below 31.7% (21.7%, 31.7%, 30.9%). I don't know why, and it's a hypothesis that "one-time" items recur. If they do, they belong in normalized earnings.
3. Your table's base row is the problem¶
With your multiples, the base row returns +2% over 12 months, and that already assumes a 19% de-rating from 40.6x to 33x. Illustrative weights:
- Equal weights: about −2%.
- 10/20/40/30: about +4%.
The return comes from the top row. It needs about 9% a quarter, which means adding $9.5B of quarterly revenue in a year versus the $7.4B added last year. You say no quarter stalled, but +2.6% (Q1'26, derived) sits right at your "Slow" row, and it happened in one of the last four quarters. That row isn't a tail. At a 28% chance of a hike and no cuts priced, a base case near +2% doesn't pay for a −26% stall row.
4. The last print is the best evidence on gaps¶
You lean on four up-gaps. The three that line up with reporting dates (your inference, since the tools don't label them) were +10.3%, +9.8% and +4.9%, and they are shrinking. The latest launched from the 08-04 close of 1,114.08, and the 09-11 close was 1,115.70. Within five weeks the market took back all of it, including a 13% round trip from 1,280.34. Today's entry is 8.3% above that September low, after a rotation day with no company news.
That doesn't predict a down-gap, because I have no edge on sign. But a gap that fully retraced is the wrong evidence for being fully long through the next one.
5. Your weight rule implies a trim¶
I accept "weight, not calendar." Then do the math. At a constant loss budget, moving from a 10% loss to a 26% loss means holding 38% of the position, about a 60% trim. A holder sized to your earlier 10%-gap standard is 2.6x over the standard you adopted today. If your core is already at the stall-row weight, we have no disagreement.
Trimming a slice isn't shorting the tail. The cost is a 4.9-10.3% up-gap missed on that slice. The benefit is avoiding a same-size down-gap, a hawkish FOMC (28% hike odds), or the −26% tail. I'm paying a known premium to cut the larger tail. Your exits don't help here either. The 1,114.08 trigger tolerates a 13% drawdown from the August high, and a gap bypasses it, so as you said, sizing is the only gap protection.
6. The open item¶
Your three-branch conditional on the 10-Q is the best part of your plan. Neither of us has read it, and its answers (cost step, goodwill vs PP&E, debt maturities) move the position by an order of magnitude. Until it's read, I'd size for not knowing.
Bottom line¶
Position: Don't initiate at $1,208.74. Holders should trim to a weight that survives the stall row, not the 10% gap. Rebuy at 1,176-1,177 or lower, or after the FOMC and Q3 print (date unconfirmed) and a read of the 10-Q. I'm not short, because revenue is strong and the up-gap tail is real. The stock just pays for repetition of last year, with no allowance for a quarter like Q1'26's +2.6%.
What changes my mind: 1. The 10-Q shows the Q2 cost step was identified and non-recurring, and the debt is term and fixed-rate. 2. Q3 shows EPS above $8.26, net margin of at least 33%, and guidance that supports roughly $45 or more of forward EPS. 3. A daily close above 1,217.65 with OBV above 349.9M and ADX above 25.
What's left between us is arithmetic, not philosophy. By your own sizing rule and your own table, the position that fits a −26% outcome is smaller than the one you'd hold today. Bear Analyst: # Bear Closing Rebuttal for LLY, as of 2026-10-14
We're down to one question: trim a third or trim half. The thesis, solvency and revenue momentum aren't in dispute. I'll concede what you've earned, hold two points, and then say where the plan lands.
1. What I concede¶
- Q1's +2.6% is weak evidence for the Slow row. It's derived from vendor TTM subtraction, and Q1 looks seasonally soft. Your ~$13.5B Q4'24 figure isn't in our dataset, so I treat it as plausible but unverified. The cleaner series is +13.1% (Q3'25), +9.6% (derived Q4), +2.6% and +16.0%, averaging 10.3%. I'm moving probability weight off Slow.
- The 13% drawdown is the wrong basis for a new buyer. From $1,208.74, the 1,114.08 line is −7.8% and the 200 SMA (1,075.89) is −11.0%. Nobody buying today paid the August high, so I withdraw "tolerates a 13% drawdown."
- −26% is an unmanaged 12-month outcome. It isn't the loss a position with defined exits takes.
- Your run-rate row is a deceleration. Nine percent a quarter is about +41% y/y by Q2'27, against +47.7% today. I set that anchor myself.
2. Where I still differ¶
The table's answer is mostly assumption. Even with your multiples and weights generous to the top rows (10/15/40/35), the expected 12-month return is about +6%:
−2.6 (stall) −1.8 (slow) +0.8 (base) +9.8 (run-rate) = +6.2
- One turn of multiple on the $37.3 base EPS is about 3.1 points of return. That is bigger than most of the reweighting we've been arguing over.
- The base row already assumes a de-rating from 40.6x to 33x. We have no peer multiples and no yield data, since FRED failed. I can't say how +6% compares with cash. With 97% "no cuts in 2026" priced, cash isn't zero.
- Fair price, a modest expected return and a −26% tail argue for a moderate position. They don't argue for conviction size.
The sizing standard is a judgment, and I'd put it above 15%. You set 15% with no down-gap sample, and you said a stall print on a ~40x name could exceed the 10.3% up-gap. Two more points:
- A 15% gap opens at about 1,027, below the 200 SMA. Every exit tier is skipped, so realized loss equals the gap, with no cushion.
- If the reported Oct 29 earnings date holds (one social post, unconfirmed), the print lands on the same day as an FOMC meeting with 28% hike odds. Our up-gap sample says nothing about those two risks resolving together.
I'll move from 26% to 20%, and I'm leaving you at 15%:
| Loss standard | Gap-open price | Weight vs. 10% standard | Trim from a 10%-sized holder |
|---|---|---|---|
| 15% (yours) | ~1,027 | 67% | ~33% |
| 20% (mine) | ~967 | 50% | ~50% |
| 26% (withdrawn) | ~895 | 38% | ~62% |
The gap between us is now 33% versus 50%, and as you said, that is a loss-budget question about the holder, not about LLY.
One consistency point on the tape trigger. I listed a daily close above 1,217.65 (OBV above 349.9M, ADX above 25) as a mind-changer. Your add sits 0.7% above today's price, so what separates "don't chase 1,208.74" from "add at 1,218" is confirmation, not valuation. I'll keep it as a tape condition. It moves me from trim to hold, not to add, because nothing in the table changes.
3. The open item still decides this¶
Neither of us could read the Q2 10-Q, so the $2.4–3.8B cost step is unexplained. So are the $15.9B jump in non-current assets and the debt maturities behind the +$11.1B in current liabilities. Your three branches are the right framework, and I'd add a deadline of before Oct 28:
- Non-recurring IPR&D and term, fixed-rate debt: I move toward your hold-and-add plan.
- Recurring opex at a ~31% margin: the Street's $47.48 looks unreachable on GAAP, and we both go to a starter.
- Short-dated debt: we both size down before the FOMC.
Bottom line¶
- Don't initiate at $1,208.74. We agree.
- Holders: trim to a weight that survives a 15–20% adverse print, which is a third to a half of a 10%-sized position. Rebuy at 1,176–1,177 or lower, or after the 10-Q is read and Q3 and the FOMC clear.
- I'm not short. Revenue momentum is real, and the 2026 up-gaps show the upside tail exists. At 40.6x trailing, a ~1% FCF yield, a ~+6% generous expected return and an unexplained cost step, though, the price leaves no margin for error.
What would change my mind: 1. The 10-Q shows the Q2 cost step was identified and non-recurring, and the debt is term and fixed-rate. 2. Q3 EPS comes in above $8.26 with net margin of at least 33%, and guidance supports roughly $45 or more of forward EPS. 3. A volume-confirmed daily close above 1,217.65 (OBV above 349.9M, ADX above 25), which moves me from trim to hold.
Research Manager¶
Recommendation: Underweight
Rationale: This debate converged a lot, but the bear won most of the contested exchanges. Under pressure the bull withdrew most of his opening pillars. The 25.5x forward P/E turned out to be just price over the vendor's $47.48 forward EPS, which is a 2027 or adjusted figure. The 3.4x operating cash flow jump was a low-base effect. 'Defensive' fell apart because beta measures correlation, not move size: LLY gapped 4.9-10.3% four times this year and fell 13% from 1,280 to 1,115 in four weeks. 'Institutions are buying' had no flow data behind it. He also conceded a wrong margin claim (only Q1'26 cleared 37%) and admitted his original tripwires sat at or below Q2 while the price needs better than Q2. What survives on the bull side is real and undisputed: revenue up 47.7% y/y with about 10% average sequential growth over four quarters, 83-86% gross margins, H1 operating cash flow at 1.11x net income, and net debt no more than about 1.9x TTM operating cash flow. Every large single-day move this year has also been up. Nobody is arguing the business or solvency is broken, and that is why this isn't a Sell. Valuation and the unknowns decided it. LLY trades at roughly 37-38x annualized GAAP EPS, 40.6x trailing, with a ~1% FCF yield. The bull's own scenario table, with multiples that move by scenario, gives about -26% (stall), -12% (slow), +2% (base) and +28% (run-rate), so his base case is roughly flat. Even weights generous to the top rows produce only about +6% expected over 12 months. That is a fair-not-cheap payoff with a fat left tail. Q2 net income fell sequentially on 16% revenue growth, leaving a $2.4-3.8B cost step below the gross line that neither side could explain. Also unverified: the $15.9B jump in non-current assets, the ~$23B liability increase, debt maturities and capex, all because nobody read the 10-Q. The FOMC (28% hike odds, 97% no cuts priced for 2026) lands Oct 28-29, possibly alongside Q3 earnings, whose Oct 29 date comes from one social post and is unconfirmed. Both sides agreed that the 1,114.08 and 1,075.89 exits can't protect against a print-day gap, so sizing is the only defense. Even the bull's final plan says a holder sized to a standard 10%-gap budget should trim about a third, and the bear says half. That shared conclusion is a modest Underweight. It is a sizing call for an unresolved cost question heading into a binary event, not a bearish call on Lilly. Explicitly missing from our data: the Q2 10-Q, a confirmed earnings date, consensus and guidance, peer multiples, rate and yield data, flow data, a capex breakout, the Q4'24 revenue figure the bull cited, and anything on MFN, tariffs or drug-pricing policy ahead of the midterms.
Strategic Actions: 1) No new buying at $1,208.74. Do not chase a +3.6% rotation day that came with no company news. Flat accounts should wait for the events to clear. Optionally, take a starter of no more than 25% of a standard allocation at 1,176-1,177 or lower. 2) Holders at standard weight should trim to about 60% of a standard allocation (roughly a 40% trim, between the bull's one-third and the bear's half) before the Oct 28 close. That sizes the position for roughly a 17% adverse print, which would open near 1,000, below every stop. Work limit sells into strength between about 1,205 and 1,217, just under the daily SuperTrend at 1,217.65. ATR is about 34 points (2.85%), so scale in tranches and avoid market orders. 3) Before the events, cap exposure at about 70% of standard. A pullback to 1,176-1,177 can rebuild from 60% to 70% at most, because the gap risk is unchanged. 4) Upgrade path. A volume-confirmed daily close above 1,217.65 with OBV above 349.9M and ADX above 25 lifts the cap to about 75%, since valuation is unchanged. Restore a full standard weight (Hold) only if two conditions are met. First, the 10-Q shows the Q2 cost step was identifiable and non-recurring and the debt is term and fixed-rate. Second, Q3 shows EPS above $8.26, net margin of at least 33%, sequential revenue growth of at least 5%, and guidance consistent with roughly $45 or more of forward EPS. Consider Overweight only if both are met and the tape confirms. 5) Downside rules. A close below 1,114.08 on rising volume, or Q3 EPS below $8.26, means cut to a starter (about 25%). A close below the 200 SMA at 1,075.89, or Q3 EPS at or below $7.94, means exit. If the 10-Q shows recurring opex at a structural margin near 31%, go to a starter. If it shows meaningful short-dated debt needing refinancing, cut to about 40% before the FOMC. 6) Priority research before Oct 28: read the Q2 10-Q. Check the IPR&D, R&D, SG&A, other income/expense and tax lines; whether the non-current asset jump is goodwill and intangibles or PP&E; debt maturities and fixed versus floating rates; buybacks; and capex. Also confirm the Q3 earnings date and obtain consensus EPS. 7) If the mandate allows, compare the cost of protective puts or a collar through Oct 29 with the trim. We have no options pricing data, so that comparison has to be done separately.
III. Trading Team Plan¶
Trader¶
Action: Sell
Reasoning: The research plan's Underweight call translates to a Sell, which here means a modest trim and not an exit. The business is strong (revenue up 47.7% y/y, 83-86% gross margins), but LLY trades at about 37-40x GAAP EPS with a ~1% FCF yield, and the bull's own scenario table gives roughly flat to +6% expected return against a fat left tail. The unexplained $2.4-3.8B Q2 cost step, an unread 10-Q, an unconfirmed Q3 earnings date (possibly Oct 29) and an FOMC on Oct 28-29 make a print-day gap likely, and the 1,114.08 and 1,075.89 exits cannot protect against one, so sizing is the only defense. Technically, today's +3.62% pop closed 4.60 above the upper Bollinger Band (1204.14) with daily z-score +2.26, ADX only 20.11, OBV still below its 349.87M peak and the daily SuperTrend still down at 1217.65, so selling into strength at 1205-1217 is better than chasing. Portfolio holdings are unknown, so apply the trim to your own position: bring a standard-weight holding down to about 60% before the Oct 28 close and do not add new exposure at 1208.74.
Entry Price: 1210.0
Stop Loss: 1237.0
Position Sizing: Trim a standard-weight holding by about 40%, to roughly 60% of a standard allocation, before the Oct 28 close, using tranche limit sells between 1205 and 1217 (no market orders; ATR is about 34). Cap total exposure at about 70% of standard, and at about 75% only after a volume-confirmed daily close above 1217.65 with OBV above 349.9M and ADX above 25. Flat accounts should not buy here and may take a starter of at most 25% of a standard allocation at 1176-1177 or lower. Cut to a starter (about 25%) on a close below 1114.08 on rising volume or Q3 EPS below $8.26, and exit on a close below the 200 SMA at 1075.89 or Q3 EPS at or below $7.94. The 1237 stop is the level where the trim thesis weakens (above the 1236.23 prior highs); consider rebuying trimmed shares above it. It does not protect against an earnings gap.
FINAL TRANSACTION PROPOSAL: SELL
IV. Risk Management Team Decision¶
Aggressive Analyst¶
Aggressive Analyst: Since neither of my colleagues has spoken yet, I'll take the arguments I expect from them head on. The Sell here isn't timid. It's a decision to act against the crowd at the exact moment the crowd feels best.
The conservative case will likely be "if you don't trust the setup, get out entirely." The neutral case will likely be "the trend is up, so hold and wait for the print." I think both miss what makes this setup tradeable.
Start with what happened today. LLY rose 3.62% on a day the Nasdaq fell about 1.65%, so this was a rotation bid and not a Lilly-specific catalyst. The Barron's headline, the StockTwits chatter and the tape all say "defensive rotation on hot inflation." That trade reverses when tech stabilizes, and one headline already says tech rebounded as AI jitters eased. We're being offered a rotation-driven pop that closed 4.60 above the upper Bollinger Band, at a daily z-score of +2.26, with ADX at only 20.11, so no confirmed trend. The daily SuperTrend is still down at 1217.65, and OBV hasn't confirmed the high. When a stock is stretched without trend or volume confirmation, I'd rather sell the stretch than wait to see if it holds.
The neutral analyst will point to the weekly and monthly SuperTrend being up and say the structure is bullish. It is, but those stops sit 23% and 55% below price. They tell us nothing about risk over the next three weeks, and no one can size a position off a 23% stop. That's why this plan leans on sizing. We don't pretend an exit level protects us from an event gap, so we cut the exposure beforehand.
Valuation is the next point. A 1% FCF yield on a $1.08 trillion company is a bet that the next two years are flawless. The bull will say forward P/E is only 25.5x, but that rests on $47.48 of forward EPS, and that's about $11.87 a quarter against $7.94 in Q2. Either that number is non-GAAP, or it's a later fiscal year, or Q3 has to be enormous. I won't pay a premium for an estimate I can't reconcile.
Then there's Q2 itself. Revenue rose 16% sequentially, gross profit rose about $3.5B, and net income fell. Net margin dropped from 37.4% to 30.9%. Liabilities jumped about $23B in a single quarter. Nobody on this desk has read the 10-Q to explain it, and I won't hold full size into a print with an unexplained cost step. Insiders sold about $18.8M between $1,150 and $1,190 over the summer, and no one has bought since August 2025. They're not screaming "cheap."
Retail euphoria also looks reactive. One poster cheers "new All Time Highs," but the close is 5.6% below the August closing high of 1280.34. Another cites a $1.14 trillion market cap, which on roughly 891M shares works out to about $1,279, the August peak and not today. People are celebrating a level the stock isn't at. Add a 28% hike probability for the Oct 28-29 FOMC (up 13 points in a week), a 97% chance of no cuts in 2026, and J&J falling after a beat and raise. A long-duration 37-40x stock walking into that has more downside than the crowd admits.
Now the cost. The bull will remind us that LLY gapped up 10.3%, 9.8%, 7.1% and 4.9% this year. That's fair, and it's the real risk to my call. But the April move started from 848 and the August one from 1114, both well below here and at far lower expectations. If the stock runs to the 1292 high, the 40% trim costs about 2.7% of position value. If it gaps to 1114, the trim saves about 3.2%, and about 4.4% if it tests the 200 SMA. The stop at 1237 sits only 2.2% above entry, and we've pre-committed to rebuy above it. That's a defined, cheap bet with a fat payoff on the left tail.
To the conservative analyst, I'd say selling everything is not bold, it's just leaving. The business is excellent, with 47.7% revenue growth and 83-86% gross margins. Keeping 60%, rebuying on a volume-confirmed close above 1217.65, and starting new positions only near 1176 let us profit from being right on the dip and stay in if we're wrong.
My call stays Sell: trim into 1205-1217 with limit orders, no chasing, and let the position size absorb the earnings risk.
FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Let me give back what I shouldn't have been holding, because the conservative analyst is right that weak arguments dilute strong ones. The retail euphoria point is gone. Thirty messages over five hours, with four or five genuinely LLY-specific, says nothing about positioning. The insider selling is gone too. $18.8M on a $1.08 trillion company is noise, and no buying after a 75 to 90 percent run is expected. The band touch is also thin: 4.6 points is about an eighth of an ATR. The chart isn't the trade. All it tells me is that we're being offered the best close in 30 days, on a bid that isn't about Lilly and that volume hasn't confirmed, so there's no reason to wait for a better sell price.
I'll also take your execution fixes. There's no pre-event rebuy line, since selling at 1217 and being told to buy at 1218 is a whipsaw machine. The 1237 level marks where the thesis weakens and isn't a trigger. The deadline binds: whatever hasn't filled by the close before the first confirmed event goes out as marketable limits. That's Oct 27 until someone confirms the earnings date. And I'd swap the GAAP EPS exits for price reaction and guidance, since acquired R&D charges can swing GAAP EPS in any quarter. Both of you are also right to drop the flat-account starter at 1176. A 2.7% dip ahead of two binary events isn't a discount.
Now the disagreements. You both lean on "all four big gaps were up," and the neutral analyst adds that they're shrinking. Look at what happened after the last one. LLY gapped up 4.9% on Aug 5 from 1114, ran to 1280 by Aug 19, and was back at 1115.70 by Sep 11. The whole post-earnings run was handed back in about three and a half weeks. The up-gaps were real, but holding through the aftermath wasn't free. It's one example, not a law, but it's the most recent one. A 10.3, 9.8, 4.9 sequence also looks like a reaction function decaying as the base rises, and J&J falling on a beat and raise is the live reminder. The earlier gaps started from 848 and 1114, when the market was still underpricing the company. At 40x trailing, I'd want to reconcile the $47.48 forward EPS before assuming it still is.
The 1.2 to 1.6 to one payoff ratio is a fair read of the extremes but the wrong test. The trim doesn't predict a drop. It decides how much variance to carry when the bull's own scenario table offers roughly flat to +6% expected return. If the stock gaps up 8%, I keep 60% of it. If it gaps down 8%, I avoid 40% of it. The payoff is symmetric around the event, and what's asymmetric is how little we're paid for the last 40%. Hike odds going from 15% to 28% in a week mean the distribution widened. The neutral analyst calls the FOMC a volatility event, and I agree. A volatility event is an argument for smaller size, not for patience.
On the 10-Q, the neutral analyst uses it to justify selling only 20% now and waiting, and I think that's backwards. The filing is already public and priced, so reading it won't move the stock, and it takes an hour. Read it before the first order goes in, then sell to target in one pass: 60% if the cost step is clean, 50% if it's recurring or short-term funded. Staging also gives up the one thing we know, which is that today is the best close in a month.
I'd also resist calling the cash flow gap "reinvestment behind the same growth," because the statement doesn't split capex from acquisitions or investment purchases. One thing in the balance sheet is my own inference, not a finding. Non-current assets rose about $15.9B in Q2 and investing outflow was about $15.4B, so the money went into something long-lived, while current liabilities rose $11.1B. That could be plants or a deal. It matters because if it's a deal, the forward EPS depends on integration and the Q2 net income dip might be explained by it. That's a lookup, but it's a lookup we haven't done, and I won't pay 25.5x on a number we haven't reconciled.
On hedging, I'd price a put spread out of curiosity, but I have no option data. Ahead of an earnings date and a Fed meeting, implied volatility is probably bid, so we'd be buying protection when it's most expensive. Selling shares is insurance with no premium and no decay, though tax treatment depends on your account. I'd skip the collar for the neutral analyst's reason, since it sells the side that has been paying.
On 50% versus 60%, we're arguing over about 0.8 points of position value. I'd keep 60% as the default. The weekly and monthly trends are up and the business is excellent, and cutting deeper becomes a market call these data can't support. The 10-Q read can move the number.
The bolder choice here isn't staying fully invested because the trend is up. It's accepting that we may watch 1292 print while holding 60%, and that the cost is defined at roughly 2.7% of position value, in exchange for entering the next 10 days with real protection and capital to re-add after the print, on evidence.
FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Let me start by giving up what I should, because you've both earned it.
Neutral, you're right that my limit orders contradict my own thesis. If I think this is a rotation pop that fades when tech settles, a ladder from 1205 to 1217 fills only if I'm wrong. If I'm right, the stock opens at 1185 and I'm still full size, watching the move I predicted. So the orders become marketable limits near the bid starting tomorrow. A close isn't a price anyone can sell at.
You're also right about August. I used it as a case for cutting before the print, but a 40% trim ahead of a 4.9% gap would have cost about two points, and the stock then went nowhere from 1114.08 to 1115.70 over about five weeks. If Aug 5 was the print, the lesson is about the aftermath: the run peaked two weeks later and gave it all back. I stretched that exhibit. Your leverage math also holds. Net debt around 1.1x EBITDA, and roughly $140 million a year of rate sensitivity even if every dollar floated, means a hawkish Fed hits this stock through the multiple, not the income statement. So the 10-Q question is earnings quality and whether a deal sits behind those liabilities, not solvency.
Conservative, your path point helps my case more than it hurts it. The stock was below its Oct 7 close until today, so the week's entire net gain is one session of tape-driven buying. I won't call that defensive, and I won't lean on a tech-rebound headline nobody can date. But one session of non-Lilly flow is the kind of bid I'd rather sell into than build a thesis on.
Now where I still push. First, the schedule. Neutral, you sell a third now, a third around the 21st or 22nd, and the rest at the deadline. What new information arrives between those dates? Nothing we know of. The filing read tonight sets the size, and after that the schedule is only a calendar that leaves exposure on. It's also weakest on the thing we're least sure of. The Q3 date comes from one social post, and if the date check pulls the deadline forward, a plan that holds its last third for the final day has no slack. So I'd front-load: two thirds over the next two sessions, the rest by about Oct 20 or 21, with Oct 27 as a backstop and not part of the plan. If the date can't be confirmed tonight, treat the earliest plausible date as the deadline.
Second, size. I'll stop fighting over five points. Your ladder works: a clean one-time charge and long-term funding gets 60%, murky gets 55%, recurring or short-term funded gets 50%. Conservative, once the leverage numbers shrink, putting the burden of proof on 60% loses force. But I'd add something neither of you did. The filing should be able to move us below 50, not just between 50 and 60. The Q2 release should carry full-year guidance, and that tells us what $47.48 is. If the cost step recurs and the forward number turns out to be non-GAAP or a later year, then 25.5x was never the multiple we're paying. We'd be holding something closer to 37x with an unexplained cost line, and I'd go to about 45%. That's my judgment, not something the data proves. And if the filing is clean, I stay at 60% without apology and call it event sizing.
Third, the hedge. Fine, price the put spread tonight if the account is taxable with a low basis. But decide before the first order, and don't let an options chain delay the sale. Implied vol going into earnings plus a Fed meeting is probably the most expensive protection of the quarter, and a spread only covers down to its lower strike. The slice we'd sell loses roughly three points of position value in a gap to 1114. If the premium is a meaningful fraction of that, I'd rather pay the tax and sell the shares.
Fourth, the re-add. Neutral, you're right that stacking ADX, a SuperTrend flip and OBV confirmation will fire after the move. ADX went from 5 to 31 to 20 in under four weeks. Guidance and a held price reaction should be the gate. But two sessions is thin when August peaked two weeks after the gap. Add back about half of what we trimmed when guidance is clean and the reaction holds, and make the second half wait for a pullback or a few weeks. Don't chase the spike.
The last two rounds have been about five percentage points. The actual bet is simpler. We're walking into two binary events on a stock at 37 to 40x trailing earnings, on a day when it got a bid for reasons that had nothing to do with Lilly. Trimming costs about three points if it runs to 1292 and saves about three if it gaps to 1114. The real payoff is the capital we have after the print, when guidance is known and the multiple is being repriced. Deciding tomorrow and reloading on evidence is the aggressive play. Sitting through at full size because the gaps have paid is the comfortable one.
FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral, you're right, so I'll drop "aggressive" as a claim of edge. By my own numbers the trim costs about three points of position value if LLY runs and saves about three if it gaps down. That's paid variance reduction going into two binary events, not alpha. What's still bold is acting on a calendar and not on price, selling into the best close in a month, and accepting up front that we may watch 1292 print while holding 60%. I'm comfortable owning that.
You're also right on the 45 rung, and I'll fix my wording. Whether $47.48 is non-GAAP or a later year doesn't change the price we pay. It only tells us how much growth is already in it. Your check works: annualized H1 EPS of $32.40 gives about 37x, and $47.48 is roughly 46 to 47 percent above that, close to the 48 percent revenue growth. So the forward number is basically "EPS grows as fast as revenue from here."
That points to where the rung should hang. H1 net margin was about 33.9 percent and Q2 was 30.9. If guidance implies margins recover toward the H1 average, the forward multiple holds up. If Q2's margin is the new base, the same revenue growth delivers roughly 9 percent less EPS than that forward number needs. That's my arithmetic and the filing has to confirm it, but it's a one-pass check and a better trigger than a label. A recurring cost step plus guidance that doesn't support the multiple earns 45.
I'll take your floor at 45 and your point that how the liabilities are funded shouldn't be a trigger. About $140 million a year of rate sensitivity doesn't justify a rung. On policy, I side with you over Conservative. A concrete, LLY-relevant MFN or tariff action moves us down a rung, and generic headlines don't. The world affairs report found nothing on drug pricing, which is a hole in the tool and not a clean bill of health, so it gets looked up tonight and either triggers or doesn't.
Here's what I'd add. Every rung on this ladder, from 60 down to 45, ends at 60 percent or lower. So the first two thirds of the minimum 40-point cut, taking us from standard weight to about 73, is no-regret under every outcome the filing can produce. The filing only decides the last 13 to 28 points. I still want it read tonight, but if that slips, the first tranche goes tomorrow anyway, and the research can't become a reason to wait.
Conservative, I agree with your re-add pace: a quarter to a third of the trim, guidance as the gate, the reaction held about a week, and a ceiling around 73 until a week after both events. I'll also take your wording on the date. If the check can't confirm anything, the earliest plausible date is the deadline.
The gap I'd close is the exits. The plan still cuts to a starter on a close below 1114.08 on rising volume and exits at the 200 SMA. Before the events, those are fair breaks of the range. After the print they have to defer to guidance. If guidance is clean and the stock gaps to 1114, that's the scenario the trim was meant to exploit. A mechanical sale of the remaining shares at the low would turn a paid hedge into a loss. If guidance is cut, we're out whatever the price. After the print there is one rule: guidance first, price second.
One last point on "fixable in a week." Neutral already showed that it isn't asymmetric, and I'd go further and put the plan in target weights. Someone already at or below 60 does nothing, and nobody sells below target. If the position has drifted above standard weight after this run, the target is still the target, not 40 percent of whatever you hold. Flat accounts stay flat, with no starter. On the hedge, decide before the first order, price a put spread only for a taxable, low-basis account, and compare the premium to the roughly three points the sale saves in a gap. If it's a meaningful fraction of that, sell the shares and pay the tax.
We're now arguing over fractions of a point on an 8 percent move. The decision is made: sell marketable limits near the bid starting tomorrow, two thirds of the cut in two sessions, the rest by Oct 20 or 21, no pre-event buys, 1237 as a review line, and rebuild slowly after the events, on guidance and not on the chart.
FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Most of this is settled, so I'll take the open items in order.
Neutral, you're right about "no-regret." I used it loosely. I meant "doesn't depend on the filing," not "costs nothing." We chose the 60 ceiling, so saying every rung ends at 60 or lower is the plan restating itself. If LLY runs to 1292, the trim costs about three points. The case is two stacked events, a thin expected return, and a few points paid to carry less variance. Conservative's extension holds on that narrower meaning. The filing doesn't decide the cut to 60, so the whole cut runs on the front-loaded schedule, and the filing only decides how far below 60 we go. Unread counts as 55.
On the H2 test, Neutral's version is right. Doubling Q2 assumes revenue stalls, so guided H2 net income over guided H2 revenue, compared with 30.9% and 33.9%, is the better check. Neutral's illustrative numbers also show something useful. H1 EPS of $16.20 plus an H2 of $17 to $18.50 puts full-year reported EPS around $33 to $35. So $47.48 can't be this year's reported number even if margins snap back to the H1 level. It's next year or an adjusted figure. That doesn't change the price we pay, but on this year's earnings that price is the mid-30s multiple, not 25.5x. I believe Lilly's releases usually give both reported and non-GAAP EPS ranges, but that's my recollection, so confirm it. Use reported against reported.
Neutral, I mostly agree on holding the ladder loosely. If Aug 5 was the Q2 print, the officer sales on Aug 7, 10 and 17 are what you'd expect in the open window right after one, which nudges that inference up a little, though it's still inference. It would also mean the market saw the cost step and bid the stock up 4.9% anyway. So the 45 rung should be rare. But I'd keep it written down. It doesn't claim the analyst community missed something. It's about how much cushion the next print has. If guidance needs margins to recover and the stock is priced for it, I'd rather have chosen that size before the headline than during it.
On exits, I'm taking Neutral's version. Conservative, you were right that I mixed up the slice we sold and the slice we kept, and the exit governs the kept slice. Clean guidance shouldn't cancel the price line, and August shows why. But zero at the 200 SMA is a bigger call than this plan has earned. With guidance intact and revenue growing near 48%, selling the last of it is a directional bet against the business. A starter at the 200 SMA is still a line with a size already chosen, so we're not debating at the lows. The full rule is this. Before the print, the trader's lines stay, minus the GAAP EPS triggers. After a clean print, a close below 1114.08 on rising volume trims a quarter of what's left, the 200 SMA takes us to the starter, and a guidance cut takes us out whatever the price.
On the rebuild, I'll take the ten to thirteen points of standard weight and the single clock that starts a week after the later of the Fed and the print. I'd add that the clock has to expire. The June 26 gap, +7.1% on 7.7M shares, doesn't line up with an earnings date if the other three are the prints. So this stock can gap up on news nobody calendars, and every day at 60 pays for that. The underweight is an event posture, not a view, and the rebuild shouldn't wait for a perfect chart.
Tonight's list is long, so here is a priority order so it doesn't become a reason to wait. First the Q3 date, then the Q2 guidance and what $47.48 is, then the 10-Q cost step, then what happened between Aug 19 and Sep 11, then CPI, VIX and concrete policy news. Tomorrow's first sale doesn't wait for any of it, because only the rungs below 60 depend on the answers.
What I'd hand the trader is this. Replace the 1205-1217 ladder and the 1210 entry with marketable limits near the bid starting tomorrow. Sell two thirds of the cut to 60 in two sessions and the rest by Oct 20 or 21. If the date can't be confirmed, the earliest plausible event date is the deadline. Go below 60 only on the ladder: 55 if murky or unread, 50 if the cost step recurs, 45 if it recurs and guidance doesn't support the multiple, and one rung down for a concrete LLY-specific policy action, never below 45. 1237 becomes a review line. There are no pre-event buys and no flat-account starter, and the targets are fractions of a standard position. Decide hedge versus sale before the first order.
I won't pretend this is alpha. What's still bold is acting on a calendar instead of a price, selling into the best close in a month, and accepting that we may watch 1292 print while holding 60%.
FINAL TRANSACTION PROPOSAL: SELL
Conservative Analyst¶
Conservative Analyst: I'll start where I agree with you, because it narrows the fight. The direction is right: the event stack, the unexplained Q2 cost step and the valuation justify taking risk down. What I reject is the idea that this is a cheap, defined trade where sizing absorbs the problem. I think the plan is both more fragile and less protective than you describe.
Your technical evidence is the weakest part of your case. The close is 4.60 above the upper band, which is 0.38% of price and about an eighth of an ATR. RSI is 60, not overbought. The weekly z-score is +1.02 and the monthly is +1.41, so only the daily is stretched. MACD is positive. ADX at 20 cuts both ways: it says the uptrend is unconfirmed, but it also says a mean-reversion call is unconfirmed. If the trim rests on a band touch, we're selling noise and will end up buying noise. The real reasons are the event calendar and the fundamentals nobody has reconciled, and the sizing should rest on those.
Next, your payoff isn't fat. By your own numbers, a run to 1292 costs 2.7% of position value, while a drop to 1114 saves 3.2% and a test of the 200 SMA saves 4.4%. That's roughly 1.2 to 1.6 to one, and only if the drop happens. The four big gaps in this year's price history were all up, and the weekly and monthly trends are up. A thin edge against that record doesn't make it a bet I'd call cheap. The trim also only protects the 40% we sell. If a print-day gap is the thesis, the 60% we keep takes the full hit, and the plan lets that creep back toward 70-75%. That isn't absorbing the risk. It's keeping most of it.
On the 1237 level, it sits 27 points above entry, which is 0.78 ATR. Today's range alone was 42 points, and the daily SuperTrend line is only 0.73% above the close. A level inside one day's noise will get tagged in routine trading. Selling at 1210 and rebuying at 1237 or higher locks in about 2.2% on the traded slice, before slippage, each time it whipsaws. That's small per round trip, but it's frequent, not rare. Your summary also loosened the written re-entry rule. The plan requires ADX above 25 and OBV above 349.9M before going to 75%. I'd go further and say no re-adds at all before the print and the Fed, because a SuperTrend flip with ADX near 20 is exactly the signal we said we don't trust.
The execution has a second problem. Limit-only tranches between 1205 and 1217 can leave us oversized into the event if the stock runs on a hot headline. The deadline should bind, not the price. Whatever hasn't filled by the Oct 27 close should go at the market, because the goal is to be at target size before the binary events, not to get 1217.
On event risk, you under-weight how much is stacked into a few days. There's an FOMC on Oct 28-29 with a hike at 28%, up 13 points in a week, and 97% priced for no cuts in 2026. There's also a Q3 print possibly on Oct 29, though that date comes only from a StockTwits post. The gaps in this stock ran from about 1.7 to 3.6 ATR, and no stop at 1114 or 1075 helps there. Your rotation story says the pop reverses when tech stabilizes. The bigger risk is that a hawkish surprise takes away the defensive bid and the multiple together. A stock at 37-40x trailing earnings and about 97x free cash flow isn't a bond proxy, and a beta of 0.45 describes ordinary days, not event days. J&J falling on a beat and raise tells us the bar is high.
You're right that the Q2 cost step is a red flag, but you stop at "nobody has read the 10-Q." That's cheap to fix this week, so fix it, and confirm the earnings date. Liabilities rose about $23B, equity is only 23.8% of assets, net debt is roughly $46B and free cash flow is about 41% of net income. If part of that is short-term borrowing, which is my inference and not something the data shows, a hawkish Fed hits the income statement as well as the multiple. Until we know, I'd give the 60% number less precision than it's getting.
I'd also drop the retail euphoria argument. It rests on 30 messages over about five hours, only four or five of them genuinely LLY-specific and bullish, and the sentiment report itself rates confidence as low. The ATH and market-cap arithmetic is clever but says nothing about positioning. Weak evidence makes your stronger points look weaker.
On the neutral case, which you pre-empted, I agree the weekly and monthly SuperTrend stops are regime markers and not risk controls. But "hold and wait for the print" doesn't work for the same reason: you can't trade the gap, you get the gapped price. And the 25.5x forward multiple depends on $47.48 of EPS, about 59% above trailing, that nobody has reconciled.
I'm not arguing to sell everything. The business is too strong and the higher timeframes are constructive. But I'd run the Sell more conservatively. Get to about half of a standard position by the Oct 27 close, not 60%, and cap at 60% until the print and the Fed are behind us. Going from 40% to 50% costs about 0.7 points more of position value if it runs to 1292, and saves about 0.8 to 1.1 points more if it drops to 1114 or the 200 SMA. Skip the 1176 starter for flat accounts, since a 2.7% dip ahead of two binary events isn't a discount. If the account allows it, look at a defined-risk hedge like a put spread or collar on the remainder, since a stop can't protect against a gap. I haven't seen option pricing, so check the cost first. Rebuy on evidence after the print, not on the 1237 line.
So I back the Sell, but as a deadline-driven, deeper cut, not a technical trade. Conservative Analyst: I'll start with what we now agree on, because it's a lot. There's no pre-event rebuy line, the deadline binds, there's no flat-account starter at 1176, the GAAP EPS exits get swapped for price reaction and guidance, and the retail and insider arguments are retired. That's a better plan than the one the trader wrote. What's left is how much to keep and how much to trust numbers we haven't checked, and on both I'd push you toward the safer side.
Neutral analyst, you say the tape treats LLY as a defensive because it went from 1188.72 on Oct 7 to 1208.74 today while hike odds went from 15% to 28%. Look at the path, though. It closed at 1166.51 yesterday, below the Oct 7 close, so for most of the week the stock was lower while those odds were rising. The whole net gain is today's 3.62% bounce on one day of tech selling. That's one session. The Aug 19 to Sep 11 stretch shows what an ordinary drift looks like in this name: 1280.34 to 1115.70, down about 12.9% in roughly three and a half weeks. A beta of 0.45 and an ATR of 34 describe a quiet tape, not that one, so I wouldn't use "defensive" to justify carrying more.
You call the $47.48 forward EPS a lookup, and I agree, but we haven't done the lookup and the arithmetic is unflattering. H1 EPS was $16.20. If $47.48 is fiscal 2026, H2 has to deliver $31.28, about $15.64 a quarter, roughly double Q2's $7.94. It's more likely a later year or a non-GAAP figure, which means 25.5x is a multiple on a number a year or more out. Until it's reconciled, I'd anchor on the 37x you get from annualized H1 EPS.
I'd also side with the aggressive analyst on cash flow. The statements don't split capex from acquisitions or investment purchases, so "reinvestment behind growth" is a story, not a finding. Here's a related piece of arithmetic. Derived liabilities rose about $23B in Q2, with current liabilities up $11.1B and non-current up about $11.9B, against only $8.4B of net financing inflow. Net financing is after dividends and any buybacks, so gross borrowing could be higher. The numbers fit borrowing, but they also fit assumed liabilities from a deal or accruals, and I can't tell which from here. When something that size is unexplained, the answer is to carry less until it's explained.
On the "paying side" argument, three gaps that plausibly line up with earnings, all up, is a tiny sample. The most recent one, Aug 5, ended with the stock round-tripping to where it started. And a deeper cut doesn't give up that side permanently, because we re-add on evidence. What we give up is about 0.8 points of position value.
Aggressive analyst, I appreciate you taking the corrections, but I disagree on two things. The first is the default. You'd keep 60% unless the 10-Q shows a problem. I'd flip it: 50% unless the 10-Q clears the problem. The neutral analyst has this right that if it's still unclear by Oct 27, we finish at 50%. The burden of proof belongs on the risk we can't explain. You also say the gap between 50% and 60% is under a point and that cutting deeper is a market call the data can't support. If it's that cheap, it's cheap insurance against exactly the part we don't understand. And every size is a market call, including 60%. The real question is which error we can recover from, and a missed 0.8 points is easier to recover from than an unexplained leverage jump on a 37x stock.
The second is "best close in a month." That's a fine reason to start, and I agree we should read the 10-Q first and then place the full order in one pass rather than staging 20% now. But 1208.74 is still 5.6% below the August closing high, so it's not an extreme. If the orders are limit-only and the stock fades tomorrow, we hold the full position at 1190 with a plan that quietly became a price hope. Price shouldn't get a vote. The deadline should.
On what happens next, a pre-event rally isn't information about the print. If LLY runs through 1237 before Oct 28, we hold target size and re-add afterward. I'd treat 1237 as a review line, not an action line. I'd also cap exposure at 60% until both the Fed and earnings are behind us, not the trader's 70% and 75% add-back levels. When we do re-add, I'd want the post-print reaction to hold for several sessions and the daily SuperTrend flip with ADX above 25 and OBV above 349.9M. The August run faded, so no chasing the post-print pop either.
On hedging, you're right that implied vol is probably bid, and I haven't seen option prices, so price a put spread rather than assume one. The neutral analyst is also right that a collar sells the side that has been paying. But there's one case where I'd still consider it. LLY is up roughly 75 to 90% from where insiders bought last August, so in a taxable account with large embedded gains, the tax cost of selling 40 to 50% could eat a meaningful part of the insurance benefit. There, a put spread or collar on the remainder is a reasonable second-best. Otherwise, selling shares is simpler and has no decay.
Finally, notice how many of our blind spots point the same way. The macro data tool returned nothing. There was no coverage of drug pricing, tariff or MFN policy this week, and the report said that's a gap, not a clean bill of health. The Q3 date comes from a social media post, and if it's right, the Fed decision and earnings could land on the same day. When the unknowns stack up like that, a conservative carries less.
So my plan is to read the 10-Q and confirm the date first, then sell to 50% in one pass between 1205 and 1217. Go to 60% only if the cost step and the liabilities check out clean. Whatever hasn't filled by the Oct 27 close goes out as marketable limits, and we re-add only after the events, on evidence.
FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start with what I'm giving up, because several of your corrections are right.
Neutral, you're right on leverage. About 1.1 times net debt to EBITDA, and roughly $140 million a year of rate sensitivity if every dollar floated, is not a stressed balance sheet. My line about a hawkish Fed hitting the income statement was an inference that doesn't survive the arithmetic. One caveat is that the EBITDA figure is the vendor's and the fundamentals report couldn't reconcile its margins to GAAP. Against trailing net income, net debt is closer to 1.7 times, which is still fine. I'll drop solvency as an argument.
What stays is that liabilities rose about $23 billion in one quarter while net financing was only $8.4 billion. Something on the order of $10 billion or more didn't obviously come from borrowing, though that leans on my own estimates of dividends and buybacks. That's a question about earnings quality, as you said, and the filing answers it.
You're also right that a tool outage is a reason to go look, not a reason to size down. And stacking ADX, a SuperTrend flip and OBV confirmation would mostly fire after the move, so I'm retiring that gate.
Aggressive, I'm glad the orders are now marketable limits. That was the point I cared about most: price shouldn't get a vote, the deadline should. I'll also take your 45% rung. If the cost step recurs and the forward EPS turns out to be non-GAAP or a later year, 25.5x was never the multiple we're paying, and going below 50 is the consistent answer.
That leaves three places where I still push.
First, the schedule. Neutral, spreading the sales to Oct 21-22 buys nothing. The only thing that arrives between now and then is price, and we've agreed not to react to price. Your deadline also has a hole. It defaults to Oct 27 and moves earlier only if the check confirms an earlier date. If the check simply fails to confirm anything, you keep Oct 27 even though the only source for the date is one social post. I side with Aggressive on front-loading: two thirds over two sessions, the rest by Oct 20 or 21, Oct 27 as a backstop, and the earliest plausible date as the deadline if nothing is confirmed.
Second, the re-add, which is now the part of the plan that worries me most. You both say to add back about half of what was trimmed once guidance is clean and the reaction holds. If we trim to 60%, half the trim is 20 points, so we'd be back at 80% of standard within a couple of sessions of the print. That's above the 70-75% ceilings in the trader's own plan.
August is the exhibit again. The gap was Aug 5, the high was Aug 19, and by Sep 11 the stock was back at 1115.70. Two sessions of a held reaction told you almost nothing then. Aggressive, you say the real payoff is the capital we have after the print. That's only true if we deploy it patiently, and reloading fast hands the benefit straight back.
I'd keep guidance as the main gate, as Neutral says, and require the reaction to hold for about a week. I'd make the first add roughly a quarter of the trim, which is about 70% of standard, and stay under 75% until the Fed and the print are well behind us. The rest comes on a pullback or after a few weeks.
Third, the ladder needs to say what bad news does. Neutral, 55% for a murky cost step is fine. But if tonight's check of CPI, the VIX and drug-pricing headlines turns up something real, like MFN or tariff language, that moves us one rung down. It shouldn't be a footnote. A clean filing also caps at 60%, and it doesn't talk us back up to 70. All of this is a fraction of a standard position. If your holding has drifted well above standard weight after this run, the target is still the target, not 40% of whatever you hold.
On the hedge, I agree with where you've landed. Decide before the first order, and price a put spread only if the account is taxable with a low basis. Compare the premium to the roughly three points of position value that selling saves in a gap to 1114. If it's a meaningful fraction of that, sell the shares and pay the tax. A put spread also protects only down to its lower strike, so it's no substitute for being smaller.
The remaining gap between us is small. The difference between 50 and 60 is worth under a point on an 8% move, and the ladder settles it. What matters is the re-add pace and the deadline mechanics, because that's where a sound plan quietly turns back into full exposure when the stock is most expensive and the news most uncertain. If we end up a bit small, we can fix it in a week. If we're full and wrong, we can't undo it.
So my plan is to read the filing tonight and confirm the date. Then set size from the ladder: 60 if clean, 55 if murky, 50 if recurring or short-term funded, 45 if recurring and the forward EPS isn't what the multiple assumes, and one rung lower for any adverse policy finding. Sell two thirds in two sessions at marketable limits and the rest by Oct 20-21. Make no pre-event buys, and re-add slowly after the events, on evidence.
FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Let me start with what I'm giving up. Neutral is right about my "fixable in a week" line. If we're at 55 and it gaps up 8%, we buy higher, and that's as permanent as being full into a drop. I'm retiring it as a rule. The smaller, honest version is that the bull's own scenario table gives roughly flat to +6% expected return, and the trim moves about three points either way. When the expected return is that thin, giving up a few points of upside to carry less variance into two binary events is a fair price. I'll call it variance reduction, like you two. I'm also fine dropping short-term funding as a trigger and limiting the policy rung to concrete, LLY-specific actions.
Aggressive, your no-regret argument is right, but you stopped one step short. You said every rung ends at 60 or lower, so two thirds of the minimum cut is no-regret and the filing decides the last 13 to 28 points. Follow that through. If no outcome of the filing leaves us above 60, then the entire 40-point cut is no-regret, not just the first 27. The filing doesn't decide whether we sell the last 13 points. It only decides whether we go below 60, by zero to fifteen points. So the full cut to 60 should run on the front-loaded schedule regardless, and the filing adds to it. I'd also write down one default: if the filing hasn't been read by the time the last tranche is due, unread counts as murky, which is 55, not clean.
I like your margin test for the 45 rung, and I'd reduce it to one number. Take full-year guidance, subtract the H1 reported EPS of $16.20, and that's the implied second half. Q2's pace annualizes to about $15.90 for a half. If the implied second half is around $16, there's no step-up, and we're paying about 37x for flat earnings whatever the $47.48 is labeled. If it's materially higher, the margin is coming back and the forward multiple has support. Compare reported to reported. If the release only gives an adjusted figure, the comparison is muddy, and muddy means 55.
Where I part ways with you slightly is the exit rule. You want guidance first and price second after the print. I'll take half of that. A guidance cut means we're out whatever the price. But I wouldn't let clean guidance cancel the price line. Your August exhibit cuts against you here. The stock fell 12.9% from 1280 to 1115 in three and a half weeks, and nothing in our data explains it as a change in the business. If guidance is clean and the stock still gaps to 1114, that's the J&J pattern of a beat, a raise and a falling stock. That's a multiple repricing, and clean guidance can't clear it.
You also said a mechanical sale at the low turns a paid hedge into a loss, but that mixes two positions. The trim saved about three points on the slice we sold. The exit decides what to do with the slice we kept, which has just taken the hit. If we want an override, we should pre-commit its form. With clean guidance, a close below 1114.08 on rising volume cuts a defined step instead of going straight to a 25% starter, and we make no re-adds until it stabilizes. The 200 SMA at 1075.89 stays a hard line. By then the stock is about 11% below here and has broken its range, and I'd rather have a line than a debate at the lows.
Neutral, you're right that my ceiling needed an end date, since a cap that never lifts is its own market call. I'd just define the clock. It starts one week after the later of the Fed decision and the print, and it requires clean guidance and a reaction that has held. If both land on the 29th, that's one clock, not two.
So here's where I land. Tonight we read the filing and the Q2 release guidance, confirm the date, and check CPI, VIX and concrete policy news. If the date can't be confirmed, the earliest plausible date is the deadline. Tomorrow we start selling at marketable limits near the bid. Two thirds of the cut goes in two sessions and all of it to 60 by Oct 20 or 21, with the filing adding the 55, 50 or 45 rungs on top and unread counting as 55. There are no pre-event buys, 1237 is a review line, and the target is a fraction of a standard position. The exits are guidance and price, with the graded override above. We rebuild slowly after the events, on evidence and not on the chart.
FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Most of what's left is mechanics, so I'll say where I move and then spend my time on the one place the plan is still soft.
I move on three things. First, the 200 SMA. A starter there instead of zero is fine with me. What I cared about was a size chosen in advance, so nobody is debating at the lows, and a starter does that. Second, the clock. Aggressive, the June 26 gap is a good catch. A 7.1% jump on 7.7 million shares that doesn't line up with a print, as far as we can tell, says this stock can gap with no calendar, which is a real argument against sitting at 60 indefinitely. If the Fed and the print both land on the 29th, my clock lifts on Nov 5 and the rebuild starts then, chart or no chart. Third, Neutral, you're right that I read the August fade as repricing when what I actually have is a hole in the news data. I'll take the lookup, and here is how it should matter. If there was a concrete cause, the fade tells us less about this tape. If there was nothing, the stock drifted 12.9% in three and a half weeks on its own, and I'd take the slow end of the rebuild, ten points and not thirteen.
I'm also fine with the 45 rung staying rare. Aggressive has the right framing: it isn't a claim that the market is wrong about ten-week-old numbers, it's a size for how much cushion the next print has. I'd add that if Aug 5 was the Q2 print, the stock gapped up 4.9% on a quarter where net income fell sequentially. That suggests the market trades revenue and guidance, not GAAP margin, so the ladder measures earnings quality and not the likely reaction. That's fine for setting size, but nobody should read a clean filing as a forecast of a good day.
Now the soft spot. A lot of this plan now hangs on the word "clean." Clean guidance sets the size of the step after a break of 1114. Clean guidance plus a held reaction lifts the cap. Clean guidance is what stops us from going to zero at the 200 SMA. Nobody has defined it. After the print, with the stock up or down seven or eight percent, the definition will bend toward whatever the price just did. A flat guide will look fine after a gap down, and a modest raise will look great after a gap up. So write it down before the print. Something like full-year revenue guidance at or above the prior midpoint, reported EPS guidance not cut, and nothing in the release or call that walks back margins. Adapt it to what the release actually reports, and compare reported with reported. Do the same for "held." Pick the pre-print close as the number, and the week's closes either stay on the right side of it or they don't. Remember the J&J lesson too. A print can meet the definition and the stock can still fall, which is why the price lines stay in force even when guidance is clean.
The second thing is about our own discipline. The risk I worry about most isn't any of the numbers. It's the plan quietly turning into "we'll sell once the lookups are done." Aggressive, your line that tomorrow's first sale doesn't wait for any of them is what makes the plan robust, and I'd put it first in what goes to the trader. Unread means 55, an unconfirmed date means the earliest plausible date, and no answer means the default, not a delay.
Third, one thing none of us has said. The rotation that lifted LLY today lifted MRK, ABBV, JNJ and UNH too. If the caller holds those, trimming LLY to 60 doesn't reduce the rotation exposure, it just moves it around. The target weights should be read against the whole defensive sleeve, not LLY alone. And alongside the hedge-versus-sale decision, choose which lots to sell before the first order, not after.
So I back the plan on the table, with "clean" and "held" defined in writing before the print. It's variance reduction with no claimed edge, executed on a calendar and not on price, with a rebuild that starts on a known date and is sized on evidence.
FINAL TRANSACTION PROPOSAL: SELL
Neutral Analyst¶
Neutral Analyst: I'll start with what you two agree on, because I'd keep it. Both of you want to be smaller going into Oct 28-29, both accept the business is excellent, and neither wants out entirely. I agree with that. My objection is that each of you has attached a weak argument to the skeleton, and the weak arguments distort the details.
Aggressive analyst, your technical case is the thinnest part. The close is 4.60 above the upper band, about an eighth of an ATR. RSI is 60, MACD is positive, and only the daily z-score is stretched. Volume was about 1.4 times average and the candle closed in the upper 81% of its range, which doesn't look like a blow-off. Your sell zone also runs up to 1217.65, and your rebuy trigger is a close above 1217.65. You could sell the last tranche at 1217 and be told to buy back at 1218. That's a whipsaw machine, not a risk plan. The evidence that the rotation unwinds soon is an undated headline saying tech rebounded, so we don't know which day it was.
I'd also be careful with the rates story you both lean on. LLY rose 3.6% on a hot-inflation day. It closed at 1188.72 on Oct 7 and sits at 1208.74 now, while hike odds roughly doubled from 15% to 28%. One week isn't a regime, but so far the tape treats this stock as a defensive, not a bond proxy. The base case is a 70% hold, and a hawkish surprise could just as easily deepen the tech sell-off and extend the rotation. I'd treat the FOMC as a volatility event, not a directional argument.
On valuation, the 1% FCF yield is real, but H1 operating cash flow was $16.0B against $4.75B a year ago. A lot of the gap to FCF is reinvestment behind the same growth. The $47.48 forward EPS looks mostly like a different-year, adjusted-versus-GAAP gap, which is a lookup and not a reason to distrust the multiple. And $18.8M of officer sales on a $1.08 trillion company is noise.
Conservative analyst, you're right on the deadline, and I'm taking it. You're also right to skip the 1176 starter for flat accounts. Don't open a position into the print.
But you're giving 50% versus 60% a precision the facts don't support yet. The choice turns on whether the Q2 cost step is a one-off, like acquired in-process R&D, or something recurring or short-term financed. That's a 10-Q read, not a debate. And "the 60% keeps the full hit" applies equally to your 50%. A 8% gap costs 4.8% of position value at 60% and 4.0% at 50%, so we're arguing over about 0.8 points.
The tail also isn't one-sided. All four big gaps this year went up, and three of the dates (Feb 4, Apr 30, Aug 5) look like they match earnings, though that's my inference. The sizes were 10.3%, 9.8% and 4.9%, so shrinking but all up. A deeper cut gives away more of the side that has been paying, and a collar on the remainder sells that side outright. I'd price a put spread, but I wouldn't collar.
My plan is to keep the Sell as a trim, not an exit, and split it in two. Sizes are in fractions of a standard position, since I don't know your book.
Tranche one is now. Sell about 20% of a standard position with limits between 1205 and 1217. Selling into a 30-day closing high is reasonable.
Tranche two depends on two facts you can get this week. Read the Q2 10-Q and confirm the Q3 date on Lilly's investor relations page. If the cost step is explained as a one-time charge and the new liabilities are long-term, finish at 60%. If it's recurring, short-term funded, or still unclear by Oct 27, finish at 50%. Either way the deadline binds. Whatever hasn't filled by the Oct 27 close goes out as marketable limits. LLY trades billions a day, so slippage is trivial next to gap risk.
I'd drop 1237 as a pre-event rebuy line, since it's 0.78 ATR from entry. Re-add after the print and the Fed, on evidence: guidance, the price reaction, and the daily SuperTrend flip with ADX above 25 and OBV above 349.9M.
I'd also change one of the trader's exits. The price triggers at a 1114.08 close on rising volume and the 200 SMA at 1075.89 are fine. The EPS triggers of 8.26 and 7.94 are GAAP numbers, and acquired R&D charges can swing GAAP EPS in a quarter. I'd expect the stock to trade on adjusted EPS, revenue and guidance, so I'd swap those for the price reaction and guidance.
The result is a position that costs roughly 2.7 to 3.4 points of position value if the stock runs to 1292. It saves roughly 3.2 to 4.0 points if it drops to 1114, and 4.4 to 5.5 if it tests the 200 SMA. That's a modest, evidence-adjustable edge, and it leaves us holding half or more of a business that has gapped up repeatedly.
FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: Let me start with where you've moved me.
Aggressive, I only suggested selling 20% now because the 10-Q hadn't been read, and reading it takes an hour. So read it tonight and size off it tomorrow. Conservative, you're right on the path. LLY closed at 1166.51 yesterday, below the Oct 7 close, so the whole week's gain is today's bounce. I'll retire "defensive" as a label, though that also retires "bond proxy." One session doesn't tell us how LLY responds to rates, which is why the Fed is still a volatility event to me and not a directional argument. I also want to take back my own re-add rule from last round, a SuperTrend flip with ADX above 25 and OBV above 349.9M. I'll explain below.
Aggressive, your execution has an internal contradiction. The thesis is that the rotation pop reverses when tech stabilizes. The orders are limits at 1205 to 1217, and the upper part of that range only fills if the pop holds. If the thesis plays out quickly and LLY opens at 1185, you're still full size and watching the thing you predicted. If today really is the best close in a month, the consistent move is to start selling tomorrow near the market. A close isn't a price you can sell at.
You also slid from "fat payoff on the left tail" to "the payoff is symmetric." The second is more honest, but then this is a risk-budget decision around two events, not an edge, and we should call it that.
I read your August exhibit differently. From the 1114.08 close on Aug 4 to 1115.70 on Sep 11, the stock went nowhere. If the Aug 5 gap was the print, which is only my inference, a 40% trim beforehand would have cost about two points of position value. An evidence-based rebuy would probably have landed in a run that peaked at 1280 two weeks later. What would have paid was selling into the run after the print. August is a lesson about the aftermath, not about cutting deeper before the print.
Conservative, on the leverage, the vendor numbers imply debt around $55B and net debt around $46B against about $41.7B of trailing EBITDA. That's a bit over one times, and even if EBITDA is adjusted and generous, it isn't a stressed balance sheet. The Fed channel into the income statement is also tiny. Twenty-five basis points on $55B, assuming every dollar floats, is about $140 million a year, roughly half a percent of trailing net income. A hawkish Fed is a multiple risk for this stock, not an earnings risk. The 10-Q matters for earnings quality: does the Q2 cost step repeat, and is a deal behind it? That shrinks the "unexplained leverage" side of your recoverable-error comparison, so the case for putting the burden of proof on the 60% is weaker than you've made it.
On stacking unknowns, I'd split them into two kinds. The 10-Q, the earnings date and what the $47.48 is are lookups. The FRED failure and the missing policy coverage are holes in our tools, not facts about the world. A tool outage is a reason to go look, not a reason to size down. Check the CPI print, the VIX and drug-pricing headlines tonight along with the filing, and size down if something turns up.
The re-add gate is where I'd push back hardest, including on my own earlier version. ADX went from under 5 on Sep 18 to over 31 on Oct 7 and back to about 20. Requiring an ADX above 25, a SuperTrend flip, OBV above its peak and several sessions of a held reaction will mostly trigger after the move. In August the stock peaked two weeks after the gap. I'd make guidance and a multi-day hold of the price reaction the main gate and use the indicators as tie-breakers.
On the tax point, I agree it can favor a hedge over selling. But the insiders' $634 to $692 buys tell us nothing about the caller's basis, which we don't know. If the basis is low and the account is taxable, price a put spread on the slice you'd have sold. Otherwise sell shares.
We've now spent three rounds on about 0.8 points of position value. Since the filing gets read before the first order, the default only matters if the filing doesn't settle it. If the cost step is a clean one-time charge and the new liabilities are long-term, finish at 60%. If it's recurring or short-term funded, finish at 50%. If it's still murky, finish at 55%. That looks like splitting the difference, but when the evidence fits both readings, the middle is the honest size. Being five points off costs about 0.4 points on an 8% gap.
So here's my version of the plan. Tonight, read the 10-Q, confirm the Q3 date and the forward EPS definition, check CPI, VIX and policy headlines, and price a put spread if the account is taxable with a low basis. Tomorrow, make one decision and execute it on a schedule. Sell roughly a third of the cut in the next session or two at marketable limits near the bid. Sell another third by about Oct 21 or 22. Sell the rest by the deadline at marketable limits. The deadline is the close before the earliest confirmed event, which could be earlier than Oct 27 if the date check says so. LLY liquidity makes slippage trivial against gap risk.
Make no new buys, no flat-account starter and no pre-event re-add, and treat 1237 as a review line. After the events, if guidance is fine and the reaction holds for a couple of sessions, add back about half of what was trimmed. Add the rest over the following weeks, and don't chase a post-print spike. Keep the 1114.08 and 200 SMA exits, and replace the GAAP EPS exits with price reaction and guidance.
That keeps 55 to 60% of a business that has gapped up repeatedly, takes a modest bite out of the event risk, and leaves room to rebuild without waiting for a perfect chart.
FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We've converged enough that the fight is now about mechanics, so I'll go through them and say where I'd still push on each of you.
Schedule first. You're both right, and I'm giving it up. I spread the sales out to the 21st or 22nd without being able to name any information that arrives in between, and the only thing that arrives is price, which we agreed not to trade on. The deadline hole Conservative pointed out also mostly disappears once we front-load. If two thirds is done in two sessions and the rest by Oct 20 or 21, the date check only matters if earnings come before about Oct 22, and that takes minutes to rule out tonight. So I'll take two thirds fast and the rest by the 21st, with the close before the FOMC as the hard backstop.
Aggressive, I'd stop calling this the aggressive play. By your own numbers it costs about three points if LLY runs and saves about three if it gaps, so it's variance reduction with roughly zero expected value. The capital after the print isn't free either. If guidance is clean and the stock gaps up, you reload above where you sold. That's the premium for sleeping through two binary events. It's worth paying, but it isn't alpha.
I'd also push back on your 45% rung. You treat "the forward EPS is a later year or non-GAAP" as a bad finding, but for a vendor forward number that's the ordinary case. Even if $47.48 is a later year, the price you pay is the same. All you learn is how much growth is already in it. The H1 run rate of $32.40 gives about 37x, and $47.48 is about 47% above that, in line with revenue growth of roughly 48%. What should move the size is whether full-year guidance implies an H2 step-up that supports the multiple. So I'd tie the 45 rung to a recurring cost step plus guidance that doesn't support the multiple, not to what the number is labeled.
Conservative, your line that a bit small can be fixed in a week while full and wrong can't be undone isn't asymmetric. This stock has gapped up four times this year, and if we're small and it gaps up 8%, we can't undo that either. We just buy higher. Both errors are permanent in price terms. The real difference is that one hurts more than the other, which is a reason for a modest tilt, not a rule.
The ladder also needs a floor. Stack a recurring cost step, a bad forward-EPS finding and a one-rung policy penalty and you get to 40% or lower, which is no longer the modest trim the trader wrote. I'd accept a policy rung, but only for a concrete, LLY-relevant finding like a real MFN or tariff action, not generic headlines, and I'd floor the whole ladder at 45. Anything lower is a thesis change and needs its own evidence. I'd also drop "short-term funded" as a trigger. We showed the rate sensitivity is about $140 million a year, so how the liabilities are funded matters much less than whether the cost step repeats.
On the re-add, your math is right and mine was sloppy. Half of a 40-point trim is 20 points, which puts us at 80% right after the print, above the trader's own ceiling. I'll go to roughly a quarter to a third of the trim, so about 70 to 73% of standard, once guidance is clean and the reaction has held about a week, which August says is the minimum. The rest comes on pullbacks or over the following weeks, with no chasing. But your ceiling needs an end date. "Under 75% until the events are well behind us" is vague enough to become a permanent underweight, which is its own market call. I'd define it as one week after both the Fed and the print, with the reaction held.
So the plan is this. Tonight, read the 10-Q and the Q2 release guidance, confirm the Q3 date from Lilly's investor relations page, find out what the $47.48 is, and check CPI, VIX and policy headlines. Price a put spread only for a taxable, low-basis account, and decide hedge versus sale before the first order. Size from the ladder: 60% if the cost step is explained as one-time, 55% if it's murky, 50% if it recurs, 45% if it recurs and guidance doesn't support the multiple, one rung down for a concrete adverse policy finding, and never below 45. A clean filing doesn't talk us above 60 before the events, and the target is a fraction of a standard position, not 40% of whatever you hold. Sell with marketable limits near the bid starting tomorrow, two thirds in two sessions and the rest by Oct 20 or 21. Make no pre-event buys and treat 1237 as a review line. Keep the 1114.08 and 200 SMA exits, and swap the GAAP EPS exits for guidance and price reaction. Rebuild slowly after the events, on evidence.
That leaves us holding 55 to 60% of a business that has gapped up repeatedly, with the event risk meaningfully reduced and room to rebuild.
FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We've converged on nearly everything that matters, so I'll stay with the places where each of you is still stretching, then say what I'd do.
Conservative, you're right that the cut to 60 doesn't depend on the filing, and I'll take your rule that an unread filing counts as 55. Aggressive, you're right that guidance should set the size of a step. But I'd retire "no-regret" for both of you. The cut is independent of the filing, which isn't the same as free. We chose the 60 ceiling, so "every rung ends at 60 or lower" is the plan restating itself, not evidence for it. If LLY runs to 1292, the trim costs about three points of position value. The real justification is the one you've both given: two stacked binary events, a thin expected return, and a paid reduction in variance. I'd make that cut, but I wouldn't call it costless.
Conservative, your implied second-half test has a flaw to fix before anyone uses it. Doubling Q2's $7.94 gives about $15.90, but that assumes revenue stops growing. Hold Q2's 30.9 percent margin, let revenue grow 4 percent a quarter, and H2 comes out around $17. Return to the H1 margin of 33.9 percent and it's closer to $18.50. The 4 percent is my assumption, so treat those as illustrative. An implied H2 of $16 would mean margins got worse, and $17 would mean Q2's cost step is the new base. The better test is guided H2 net income over guided H2 revenue, reported against reported, compared with 30.9 and 33.9. Aggressive's margin framing was right, and the dollar version dropped the revenue growth.
Conservative, you also read the August fade as multiple repricing because nothing in our data explains it as a business change. But our tools returned no dated news at all, and your own rule is that a hole in the tools isn't a clean bill of health. Add it to tonight's lookups: what happened between Aug 19 and Sep 11? If it was a policy headline or a trial readout, that's a different risk from the J&J pattern, and it changes what a post-print break of 1114 would mean.
Aggressive, you said the filing is public and priced, and I'd push that further. The Aug 5 gap looks like the Q2 print, which is my inference. If so, the market has known about the cost step for ten weeks, and the stock has gone to 1280, to 1115 and back to 1209 with it in hand. So I'd hold the ladder loosely. The filing and the Q2 guidance tell us about earnings quality, but they don't hand us a five-point answer. If we conclude that 25.5x doesn't hold from ten-week-old public numbers, we're claiming to see something the whole analyst community missed. That's possible, but the 45 rung should be rare, and murky should mean 55 and move on.
On the exits, you're each half right, and the halves fit together. Price lines decide when we act, and guidance decides how big the step is. Before the print, the lines stay as the trader wrote them, minus the GAAP EPS triggers. After a print with clean guidance, a close below 1114.08 on rising volume trims a defined step of what's left, say a quarter, with no re-adds until it stabilizes. The 200 SMA takes us to the starter, not to zero. A guidance cut takes us out whatever the price. Aggressive, that keeps us from dumping the remainder at the low on clean news. Conservative, it keeps a line in place instead of a debate at the lows. Going to zero on a moving-average break, in a business growing revenue near 48 percent with guidance intact, is its own market call.
On the re-add, define it in points of standard weight, about ten to thirteen, not as a fraction of the trim. Otherwise the deeper rungs quietly make the add bigger. The ceiling near 73 lifts one week after the later of the Fed and the print, if guidance is clean and the reaction has held. If both land on the 29th, that's one clock.
So here's the plan. Tonight, read the filing and the Q2 guidance, confirm the date, find out what the $47.48 is, check CPI, VIX and concrete policy news, and look up what drove the August fade. Tomorrow, start selling at marketable limits near the bid. Two thirds of the cut goes in two sessions, and the rest to 60 is done by Oct 20 or 21. Go below 60 only if the lookups support it, and treat unread as 55. Price a put spread only for a taxable, low-basis account, and decide hedge versus sale before the first order. Make no pre-event buys, treat 1237 as a review line, and rebuild slowly after the events on guidance, not the chart.
That takes Aggressive's urgency and Conservative's discipline without claiming an edge we don't have. It's a modest trim that moves about three points either way, and it leaves us holding most of a business that has gapped up repeatedly.
FINAL TRANSACTION PROPOSAL: SELL Neutral Analyst: We're down to mechanics, so I'll take your last two responses in turn and then say what I'd hand the trader.
Aggressive, I agree with putting the first sale ahead of every lookup. It should be the first line of the handoff, as Conservative said. The H2 test is also right now: reported against reported, margin compared with 30.9 and 33.9. But I'd stop leaning on the "mid-30s multiple on this year's earnings" line. It's true, but it compares two different years. $47.48 over a $34 full-year number is roughly 40% growth against revenue growing about 48%. That supports caution, but it doesn't carry the sizing. The two events do. Keep the 45 rung tied to margins and guidance, where you put it, and don't spend valuation rhetoric on it.
Conservative, you found the soft spot, and "clean" and "held" do need to be written down before the print. But your definitions have problems. "Reported EPS guidance not cut" brings back the GAAP problem we just removed from the exits. An acquired R&D charge from a deal can cut reported EPS guidance in a quarter where the business is fine, and Q2's cost step may be that very thing. So clean should mean revenue guidance at or above the prior midpoint, with any EPS guidance change explained by named one-time items and not by margin. That's still a low bar for a company growing near 48%, and J&J beat and raised and fell anyway. So clean is a dial for step size and nothing more.
"Held" has a worse flaw. Measured against the pre-print close, an up-gap only fails if the entire gap is erased. If Aug 5 was the print, which is still inference, the stock went from 1114 to 1280 and back to 1115.70 without ever closing below the pre-print close of 1114.08, so that test would have passed for five weeks. Held is a filter against an immediate failure, not a timing signal. The pacing does the real work: a first add about a week after the print, and the rest on a pullback or over several weeks.
Your clock also collides with your own exit rule. You say the rebuild starts Nov 5 "chart or no chart," but the exit rule says no re-adds after a break of 1114 until the stock stabilizes. If the print gaps LLY to 1100, those two instructions contradict each other. The clock should lift the cap, not force a purchase. It gives permission, and a price line that has been hit takes precedence. The "later of" clock also only works if the date is confirmed. If the print lands a week after the Fed, we're at 60 for most of November.
I'd also drop the ten-versus-thirteen split that depends on what the August lookup shows. That puts three points of weight on the answer to a news-gap question. Pick the middle and let the pacing handle it.
Your sleeve point holds for the Fed leg but not the earnings leg, since the print is LLY-specific. So it's one line in the handoff: if the caller holds the other defensives, count them. Choosing lots before the first order is a good practical point, and I'd keep it.
Here's something none of us has said. As far as the technical report shows, the four big gaps this year were all up. The losses came as drifts: the slide to 848 by late April and the 12.9% fade from 1280 to 1115. I don't have the daily path, so I can't rule out sharp down days. But the trim protects against a down-gap this stock hasn't shown this year, while the drifts it has shown happen after the events, when we'll be at 60 and rebuilding. That's the argument for keeping the price lines and the slow rebuild exactly as written. It's also why I wouldn't cut deeper than the ladder allows. The trim is a modest fee for real event risk, not a forecast.
So the handoff is this. Start selling tomorrow at marketable limits near the bid. Sell two thirds of the cut to 60 in two sessions and the rest by Oct 20 or 21, regardless of any lookup. Tonight, in order, check the Q3 date, the Q2 guidance and what $47.48 is, the 10-Q cost step, the August fade, then CPI, VIX and concrete policy news. Unread counts as 55, an unconfirmed date means the earliest plausible date, and lower rungs need a finding, with a floor of 45. Before the print, the trader's price lines stay, minus the GAAP EPS triggers. After it, a close below 1114.08 on rising volume trims a quarter of what's left, the 200 SMA takes us to the starter, and a guidance cut takes us out. Price lines override the clock.
The cap lifts one week after the later of the Fed and the print if guidance is clean and no price line has been hit. Rebuild about ten to twelve points of standard weight in stages, and don't chase a spike. Decide hedge versus sale and which lots to sell before the first order. Price a put spread only for a taxable, low-basis account. No pre-event buys, no flat-account starter, and 1237 is a review line.
That's variance reduction, not edge. It costs about three points of position value if LLY runs to 1292 and saves about three if it gaps to 1114.
FINAL TRANSACTION PROPOSAL: SELL
V. Portfolio Manager Decision¶
Portfolio Manager¶
Rating: Underweight
Executive Summary: Underweight LLY: cut a standard-weight holding to about 60% of a standard allocation before the Oct 28-29 FOMC and a possible Oct 29 Q3 print. This is a trim to reduce risk ahead of two events, not an exit and not a bearish call on Lilly. Start tomorrow with marketable limits near the bid: two-thirds of the cut in the first two sessions and the rest by Oct 20-21, with the Oct 27 close as the hard backstop. If the earnings date cannot be confirmed, the earliest plausible event date is the deadline. Go below 60% only if tonight's 10-Q and guidance review supports it, with a floor of 45%. Make no pre-event buys, keep the 1114.08 and 1075.89 price exits, and rebuild about 10-12 points of standard weight starting roughly one week after the later event, if guidance is clean and no price line has been hit.
Investment Thesis: Why Underweight rather than Sell or Hold. All three risk analysts converged on trimming, not exiting. The business case is not in dispute: revenue rose 47.7% y/y to $22.97B, gross margins run 83-86%, H1'26 operating cash flow was $16.0B versus $4.75B a year earlier, and net debt is about 1.1x vendor EBITDA. A rate move costs at most about $140M a year even if all debt floated, so a hawkish Fed hits LLY through its multiple, not its earnings. That rules out Sell. The trader's 'Sell' label described a partial trim, which is Underweight on this scale. Hold is also wrong, for four reasons. (1) Valuation: LLY trades at 40.6x trailing and about 37x annualized H1 GAAP EPS of $32.40, with a ~1% FCF yield and about 97x P/FCF. The 25.5x forward P/E uses $47.48 of EPS, which cannot be this year's reported figure: H1's $16.20 plus a plausible H2 of $17-18.50 gives only about $33-35. (2) The bull's own scenario table (-26%, -12%, +2%, +28%) averages about -2% with equal weights and only about +6% with weights tilted toward the upside. That is a thin expected return against a fat left tail. (3) Q2 has an unexplained cost step. Gross profit rose about $3.5B while net income fell $0.3B, so net margin dropped from 37.4% to 30.9%. Liabilities rose about $23B against only $8.4B of net financing, and nobody has read the 10-Q. (4) Two events are stacked: the FOMC on Oct 28-29 with 28% hike odds, and a Q3 date that rests on a single social media post. This year's gaps of 4.9-10.3% (1.7-3.6 ATR) mean the 1114.08 and 1075.89 stops cannot protect against a print-day move, so position size is the only real defense. The technical case is supporting evidence only, and I weight it lightly, as the Conservative and Neutral analysts argued. Today's +3.62% came on a day the Nasdaq fell about 1.65%, with no Lilly news. The close was 4.60 above the upper Bollinger band, daily z-score +2.26, ADX 20.11, daily SuperTrend still down at 1217.65, and OBV at 347.87M, below its 349.87M peak. Against that, the weekly and monthly SuperTrends are up and all four large gaps this year were up. That is why this is a modest trim and not a deep cut. Cost of the trim: holding 60% instead of 100% costs about 2.8 points of position value if LLY runs to 1292.65, and saves about 3.1 points at 1114 or 4.4 points at the 200 SMA. This buys lower variance; it is not a claimed edge. Execution, adopting the debate's revisions over the trader's original plan. Use marketable limits, not the 1205-1217 limit ladder, because that ladder only fills if the fade thesis is wrong. The deadline governs, not price. Size by a ladder in fractions of a standard allocation: (a) 60% if the Q2 cost step is a named one-time item; (b) 55% if it is murky or the filing is unread; © 50% if the cost step recurs; (d) 45% if it recurs and guided H2 net margin (reported basis) stays near 30.9% rather than recovering toward 33.9%; (e) one rung lower for a concrete LLY-specific MFN or tariff action. The floor is 45%. Holders already at or below 60% do nothing, and flat accounts stay flat (no 1176-1177 starter before the events). The 1237 level is a review line, not a rebuy trigger. Before the first order, decide between selling and hedging, and choose which tax lots to sell. A put spread makes sense only for a taxable, low-basis account and only if the premium is small relative to the ~3 points the trim saves. If the caller also holds MRK, ABBV, JNJ or UNH, count them for rate and rotation exposure. Exits. Before the print: a close below 1114.08 on rising volume cuts to a 25% starter, and a close below 1075.89 means exit. The GAAP EPS triggers are dropped because acquired R&D charges can swing them. After a clean print: a close below 1114.08 on rising volume trims a quarter of what remains, the 200 SMA takes the position to a starter, and a guidance cut means exit at any price. 'Clean' means revenue guidance at or above the prior midpoint, with any EPS change explained by named one-time items rather than margin. Write this definition down before the print. What would change the call. Upgrade path to Hold: guidance is clean, the price reaction holds for about a week, and no price line is hit. Then rebuild in stages. Price lines override the clock, and do not chase a spike. Overweight would additionally need a confirmed margin recovery and the tape to agree. Downgrade path to Sell: a guidance cut, or a close below 1075.89. Price target: 1185. Method: valuation objective from the debate's scenario table, equal-weighted: (-26% - 12% + 2% + 28%) / 4 = -2%. Applied to 1208.74, that gives 1184.6, rounded to 1185. A technical check agrees: the daily stretch points to mean reversion toward the 10 EMA (1176.39), 50 SMA (1177.17) and Bollinger mid-band (1168.60). Missing data that lowers confidence: the Q2 10-Q, a confirmed earnings date, consensus and guidance, what $47.48 actually is, peer multiples, rate, CPI and VIX data, flow data, a capex split, policy news, the cause of the Aug 19-Sep 11 fade from 1280 to 1115, and options pricing.
Current Price: 1208.74
Price Target: 1185.0
Confidence: Medium
Time Horizon: 4-8 weeks